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ABSTRACT 
 
The study was conducted to develop a technique that measures the amount 
of gadolinium based contrast agent accumulated in a head tumour by x-ray 
fluorescence, while a patient is exposed to neutrons or during external beam 
radiotherapy planning. In this research, measurements of the gadolinium 
concentration in a vessel simulating a brain tumour located inside a head 
phantom, by the x-ray fluorescence method were taken, where the Magnevist 
contrast medium which has gadolinium atom, in the tumour vessel, was excited by 
a 36 GBq (0.97 Ci) 
241
Am source that emits gamma rays of 59.54 keV, in 35.7 % 
of it’s decays, resulting the emission of characteristic fluorescence of gadolinium 
at 42.98 keV that appeared in the X-ray fluorescence spectrum. 
A Cadmium Telluride (CdTe) detector was used to evaluate and make an 
analysis of the gadolinium concentration. Determinations of the gadolinium 
content were obtained directly from the detector measurements of XRF from 
gadolinium in the exposed tumour vessel. The intensity measured by the detector 
was proportional to the gadolinium concentration in the tumour vessel. These 
concentrations of gadolinium were evaluated for dose assessment. 
The positioning of the head phantom was selected to be in the lateral and 
vertex positions for different sizes of tumour vessels. Spherical tumour vessels of 
1.0, 2.0, 3.0 cm and an oval tumour vessel of 2.0 cm diameter and 4.0 cm length, 
containing the gadolinium agent, contained concentration between 5.62 to 78.63 
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mg/ml. They were placed at different depths inside a head phantom at different 
positions in front of the detector and the source for the measurements. These 
depths ranged from 0.5 cm to 5.5 cm between the center of the tumour and 
interior wall of the head phantom surface. 
The total number of measurements in all four sizes of the tumour vessel 
was 478; 78 examinations of a 1.0 cm spherical tumour vessel, 110 examinations 
of a 2.0 cm spherical tumour vessel, 150 examinations of a 3.0 cm spherical 
tumour vessel and 140 examinations of a 2.0 x 4.0 cm ellipsoid tumour vessel.  
To measure the size and the shape of the tumour by the alternative 
radiographic method, a general x-ray machine with radiograph film was used. 
Based on that, the appropriate shape of concentration could be selected for 
therapy. The differences of optical density in the x-ray films showed that the noise 
was increased with low concentration of the Gd. Because radiographic film may 
be subjected to different chemical processes where the darkness will be affected, 
these measurements would be very hard to be quantitative. Accordingly it is 
difficult to use the film for Gd concentrations. The obtained data show that the 
method works very well for such measurements.  
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CHAPTER 1 
 
INTRODUCTION 
 The human body is composed of a huge number of cells, which have the 
ability to divide and reproduce. This is required for body growth and to replace 
cells that die during physiological function or as a result of diseases. This division 
is normally under a control system, but for any reason, if cell reproduction 
becomes independent or autonomous, in a way that does not serve a specific need, 
then a tumour will occur. 
A brain tumour is defined as any intracranial mass formed as a result of 
uncontrolled cellular growth as shown in Figure ‎1.1. Clinically, brain tumours can 
be classified as malignant or benign according to their pathological behaviour. 
Malignant tumours are either primary (i.e., originating from the brain itself) or 
secondary (i.e., originating from other locations, metastatic tumours). Primary 
brain tumours can originate from neurons, glial cells (astrocyts, oligodendrocytes, 
and ependymal cells), lymphatics, blood vessels, nerves, brain envelope 
(meninges) and skull. 
Symptoms of brain tumours vary, depending on the type, size and location 
of the tumour. Benign tumours are usually slow growing while malignant tumours 
are fast growing with rapidly progressive symptoms. Large tumours can present 
symptoms of elevated intracranial pressure such as headache, vomiting and 
altered levels of consciousness. Focal neurological signs are not uncommon in 
brain tumours. These may include weakness or paralysis, sensory loss, visual 
 2 
impairment, behavioural impairments, imbalance, personality changes and 
seizures. 
Imaging plays a crucial role in the diagnosis of brain tumours. Non-
invasive high resolution imaging modalities such as computed tomography (CT) 
and magnetic resonance imaging (MRI) have replaced older invasive methods 
such as pneumoencephalography and cerebral angiography and other techniques 
that provide a geometrical reconstruction and a three-dimensional space 
visualisation for the recognised brain tumour region. Definitive diagnosis can only 
be confirmed by histological examination of the tumour tissue, obtained either by 
means of open surgery or biopsy[1, 2]. 
The 1997 Central Brain Tumour Registry of the United States shows more 
than 14 people were diagnosed with primary brain tumours per 100,000 
population [3]. Radiation therapy plays a major role in the treatment planning by 
using ionising radiation. This is a form of energy whose absorption in tissues 
leads to a chain of physical and chemical events. These events result in the 
induction of biological damage to nucleic acids in chromosomes which are vital 
constituents of living cells. 
Nucleic acids are the main constituents of genes and carry the code for the 
genetically determined characters of the living cell. However, when repairing the 
induced damage, errors may occur. This may have two consequences. Firstly: the 
structure of the gene may change at the site of damage, which can lead to a 
genetic mutation with the appearance of new genetic characters. Most new 
characters are harmful and can lead to the occurrence of hereditable defects. 
Alternatively, it may lead to a long chain of alterations that result in the 
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transformation of the cell into a malignant one: a process that is called 
carcinogenesis. Secondly: if the damage occurs in a cell capable of division, the 
cell may not be able to complete the division cycle and may die during the 
division process. This will stop or slow down the process of production of new 
cells. This particularly influences tissues whose cells are short lived and require a 
high rate of production of new cells to replace those that are lost under normal 
physiological condition. Stoppage or slowing down of production of new cells 
would then lead to a rapid reduction in the number of tissue cells. 
Continuation of tumour growth depends on the activity of the tumour stem 
cells that have an unlimited capacity for division. In tumours, cell production 
exceeds cell production in the surrounding healthy tissue. This can occur as a 
result of nourishment or a lack of host resistance that will result in increasing the 
size of the tumour. The success of radiotherapy depends on the probability of 
killing all tumour stem cells. Consequently, we need to deliver a large dose to the 
tumour. This always involves the delivery of a large radiation dose to the normal 
tissues in the neighbourhood, and this produces various degrees of normal tissue 
damage resulting in the stoppage or slowing down of the division of normal tissue 
stem cells[4]. 
It is the task of the radiotherapist to plan an optimum treatment that can 
achieve maximal damage within the tumour and the least damage in the 
surrounding normal tissue. These treatments include neutron therapy that has been 
used since 1930 and is very effective compared with the conventional 
radiotherapy. It has the ability to deliver the maximum dose of the radiation to the 
tumour cells with minimum dose to the normal tissue around the tumour. 
 4 
In lower energy electron and photon radiation, the damage will happen 
because the atomic interactions with low linear energy transfer (low LET). With 
the fast neutrons however, the energy will be higher (high LET) and the damage 
will be from nuclear interactions. The advantage of neutron therapy is the ability 
of the neutron to deposit up to 100 times of the energy per unit intensity to the 
tumour compare with conventional high energy x-rays from linear accelerator 
radiation. This is because, following neutron interaction, charged particles like 
alpha or conversion electrons emitted following a neutron absorption deposit all 
their energy in the tumour, while high energy x-rays deposit only a small fraction 
of their energy. Moreover the cross sections of interaction of neutrons with 
Gadolinium or Boron are much higher than that of x-rays.  Also, the biological 
advantages of the neutron over conventional radiation, is that neutron has a higher 
probability of creating a double strand breakage of the deoxyribonucleic acid 
(DNA). 
The biological effectiveness is not affected by the growth stage of tumour 
cells and unlike low LET radiation does not depend on the presence of oxygen to 
be effective [5-7].  
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Figure ‎1.1: Brain tumour a radiographic image[1]. 
 
 
 
Neutron radiotherapy can be used as external beam therapy or as neutron 
capture therapy (NCT). Neutron capture treatment is an effective means in tumour 
therapy where the dose is delivered mainly to the tumour, leaving a negligible 
dose to the surrounding healthy tissue. This is unlike other radiation treatment 
methods, such as treatment with an incident external beam from a linear 
accelerator. In this case healthy tissue, in the path of the incident beam, is exposed 
during treatment. In NCT, stable therapeutic agents are delivered to the tumour 
and then exposed to neutrons. Stable agents in the tumour emit different radiation 
patterns following neutron capture, depending on the type of therapeutic agent.   
Most often gadolinium (Gd) and boron compounds are injected into the 
body and concentrate in the tumour. The dose delivered to the tumour is of prime 
interest to the therapists. Because the Gd compounds gradually build up in the 
tumour, followed by elimination, it is important to know the time when the 
highest concentration is reached, in order to give the most effective treatment. 
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The extra cellular Gd agents have been administered safely to over 10 
million patients, since gadoteridol was first approved for marketing in the United 
States in 1992 [8]. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) 
is one such agent capable of strong proton relaxation enhancement with relatively 
high in-vivo tolerance. This hydrophilic complex is rapidly excreted, 
predominately in the urine. Apparently it does not dissociate in-vivo
 
[9].  The Gd 
dose used in the irradiation experiments was four times the current accepted high 
dose in clinical MRI
 
[10].        
In recent years the stable element Gd has received a lot of attention in 
research with regards to NCT, which is a promising radiation therapy for brain 
cancer treatment [11-25]. In this type of treatment, a non-radioactive compound 
that contains Gd, an element with a high thermal neutron absorption cross section 
for neutron reactions, is introduced into the patient. There is significant 
accumulation of the agent in the tumour cells. The body is then irradiated from 
outside with neutrons. Upon absorption of thermal neutrons, the compound is 
activated and radiation is emitted, giving a highly localised dose to the tumour and 
a much lower dose to the surrounding healthy tissue. This has distinct advantages 
over other types of treatment, where healthy tissue may receive significant doses. 
Boron-10 is known for such treatment but gadolinium-157 radionuclides have a 
thermal neutron cross section of 255,000 barn and releases 7.9 MeV per neutron 
absorbed, compared with a 3,838 barn thermal neutron cross section for boron-10 
which releases only 2.79 MeV. The high thermal neutron cross section for 
gadolinium-157 may permit a reduced irradiation time and a lower neutron dose 
delivered to the healthy tissues. 
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Moreover, the Gd compound was also developed as a contrast-enhancing 
agent for MRI. Because Gd emits conversion electrons and several x-rays 
following neutron absorption, it gives a wider dose distribution than boron-10 
which gives a highly localised dose due to producing energetic alpha particles and 
lithium atoms following neutron absorption, as shown in the equation below: 
                          10
B + nth →‎
4
He + 
7Li‎+‎γ's‎‎‎‎Qvalue ≈‎2.79‎MeV           (1) 
Also, boron has poor tumour to blood ratios, poor solubility in aqueous or 
biological media, and lacks tumour specificity [26-38] . In recent work, [39] the 
two radionuclides combined were considered for treatment. Each compensates for 
the‎ other’s‎ disadvantages‎ and‎ new‎ compounds‎ are‎ being‎ developed‎ as‎ carrying‎
agents. 
In order to evaluate the dose delivered to a patient and to determine the 
duration of the irradiation, it is important to know the amount of Gd atoms in the 
tumour and the reaction rates with neutrons. After each neutron absorption, a 
fixed amount of energy is released and dissipated in the tissue. 
Current methods of measuring Gd distribution in a rat model [40, 41] 
include MRI for brain scans and neutron autoradiography with gadolinium-157.  
Neither of these techniques can be used for accurate determination of doses in the 
clinical setting. Both techniques are time consuming and the time period between 
imaging and treatment is too long. By the time a patient is imaged and prepared 
for treatment by neutron irradiation, a significant amount of Gd is eliminated. This 
is due to the Gd compound's biological half-life which is approximately 30 
minutes [42]. 
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Neutron autoradiography is the creation of an image of the target tissue on 
an x-ray film emulsion due to the radioactive material inserted into the target. This 
technique has been used on a sliced tissue sample containing Gd, but not for in-
vivo measurements [43]. It is expected to be extremely complicated for in-vivo 
measurements. Also, MRI is an expensive imaging technique that may or may not 
be available at the place where neutron irradiation is carried out.  
X-ray fluorescence (XRF) is one of the principal techniques used for 
quantitative analysis of high-Z materials. It determines the concentration and 
identity of elements and minerals. It was the first clinical method used for non-
invasive measurement of natural iodine in the thyroid gland [44]. Later, this XRF 
technique was used to measure x-ray contrast agents containing iodine in body 
tissue [45]. Since then, the technique has been used to study the elemental 
concentration of different metals such as cadmium in the kidney, mercury, 
strontium and lead in the bone tissue that are toxic to the human body if present in 
too high a concentration [46-50]. Minimum detectable lead concentrations in the 
tibia bone were between 8–35‎ μg/g‎ of‎ bone‎mineral,‎ these‎ concentrations‎ were‎
obtained when target material is exposed to radiation sources such as 
99m
Tc, 
109
Cd 
or 
157
Co  [51-53].  
In XRF, the target material is irradiated with a gamma source. A 
photoelectric effect occurs when the atom is absorbed by the gamma ray and gives 
all its energy to the electron in the inner shell that is then ejected from the atom 
and creates a vacancy. These vacancies cause the atom to be unstable. To return to 
its stable state, electrons from the outer shell move into replace the one removed. 
They produce a characteristic x-ray with energy equal to the difference between 
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the two binding energies of the corresponding shells, Figure ‎1.2. The energy of 
the emitted radiation is characteristic of the element. 
The characteristic x-ray is termed as K, L, or M to indicate the shells they 
originated from. Also, x-rays that originate from the transition of electrons from 
higher‎shells‎is‎labelled‎as‎α,‎β,‎or‎γ.‎So,‎if‎the‎replacing‎electron‎originates‎from‎
the L shell, it is labelled Kα, while the electron which is comes from the M shell is 
labelled as Kβ. 
 
 
 
Figure ‎1.2: Characteristic x-ray emission. 
 
 
Our study was conducted to start the development of a technique that 
measures the amount of Gd in a brain tumour vessel by the XRF at the same time 
a patient is exposed to the neutrons or during external beam radiotherapy 
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planning. It is intended to measure Gd concentration in the brain tumour vessel in 
a head phantom. In this method, gamma rays are allowed to be incident on the 
organ under investigation. Following the absorption of gamma rays by Gd atoms, 
characteristic x-rays are emitted and measured by a solid state detector and 
associated electronics. The intensity measured by the detector is dependent on the 
Gd concentration. The amount of Gd can be evaluated for dose assessment. 
Variables of this measurement were: tumour vessel size, tumour shape, depth of 
the tumour vessel, concentration of the Gd solution and position of the head 
phantom. 
Gadolinium atoms in the tumour vessel were excited by a 36 GBq (0.97 
Ci) americium-241 (
241
Am) source (T1/2=432.7 years), that produces 59.5 
keV gamma rays with a relative probability of 0.357 per disintegration. A 
cadmium telluride detector measures emitted characteristic fluorescence radiation. 
Because the energy of the incident radiation is greater than the binding energy of 
electrons of the Gd atom, absorption will occur mainly via the photoelectric 
effect. Characteristic of the Gd, 42.98 keV photons were measured. The observed 
count rate from x-ray peaks of the Gd was dependent on the amount of Gd present 
in the brain tumour vessel.  
A second method that depends on neutron capture gamma ray was 
attempted as well. Using this technique, neutrons from a californium-252 (
252
Cf) 
source are allowed to be incident on the tumour vessel that contains Gd inside a 
head phantom. Following the neutron capture‎(n,‎γ)‎reaction,‎ the‎emitted‎gamma‎
rays are measured by a high purity germanium (HPGe) detector and associated 
electronics. 
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The intensity of the gamma ray should be proportional to the concentration 
of Gd in the tumour vessel. Experimental work was performed, but was not 
entirely successful. The measured data and limitations of this additional method 
are presented in Chapter 2. 
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CHAPTER 2 
 
Gadolinium Concentration Analysis in a Brain Phantom 
By a Neutron Capture Process 
 
 
 
This chapter presents attempts to measure concentrations of the Gd in 
brain tumour vessels using a neutron source. It consists of five sections. The first 
section describes attempts to measure Gd; the second section presents the 
experimental method; the third section describes the calibration; the fourth section 
presents the procedure and the last section is the results and discussion. 
 
2.1 Attempt to measure Gd concentration from (n, γ) reaction 
Neutron capture therapy is a radiotherapy technique utilised for brain 
tumour treatment in which the tumour contains a non-radioactive agent. When 
exposed to neutron radiation this agent is converted it into a radioactive agent. In 
this type of therapy, gadolinium-157, which has the highest thermal neutron 
capture cross section is introduced into the tumour cells through Gd agent 
molecules such as Gd-DTPA, which were designed to penetrate the cell 
membrane and then release the Gd atom that can bind to the DNA [54, 55]. 
When the human body is irradiated from the outside by neutrons, 
gadolinium-157 atoms inside the tumour absorb a slow neutron to become 
gadolinium-158 as shown in the reaction below. Gadolinium neutron capture 
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reactions produce Auger electrons, internal conversion electrons, prompt gamma 
rays and x-rays. 
157
Gd + nth →‎
158Gd‎+‎γ + x-rays + IC e- + A e-,‎‎‎‎Q‎≈‎7.94‎MeV         (2) 
 
where IC e- are the internal conversion electrons, and A e- are the Auger 
electrons. High energy capture gamma rays can easily escape from the body and 
be measured by a high-resolution gamma detector such as a HPGe. The new 
isotope spontaneously decays with 69% of the nuclear decay yielding internal 
conversion electrons of energy 45-46 keV with range 60 µm. These electrons are 
ejected from the atoms and create a vacancy that is filled by electrons from outer 
shells, emitting x-rays or Auger electrons with 5-9 keV energies [56]. Gamma 
rays and conversion electrons released in the gadolinium-157‎ (n,‎ γ) reaction 
deliver a dose to the cells in the brain tumour, causing a number of double strand 
breaks of DNA and cell death. 
After gadolinium-157 atom in the tumour cell absorbs slow neutron, it 
produces  gamma rays, conversion electrons and Auger electrons. These electrons, 
dissipate their energy in the tumour. Gamma rays penetrates the tumour and only 
a small fraction of its energy is dissipated in it. For 944 keV emitted following a 
neutron capture, the half-value layer is 10 cm. for a bout 1 cm diameter tumour 
the calculated energy deposited will be about 7% as most of the ray leave the 
tumour without interaction. On the other hand, the range of Internal Conversion 
electrons is 60 µm and for Auger electrons about 1 µm, accordingly all their 
energies are deposited in tumour, causing a double strand break in DNA. 
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The long range component photon of 157-Gd is able to increase the dose 
received by quiescent tumour cells (i.e., cells that do not have strong uptake of the 
carrying agent) [57]. Studies indicate that concentrations of‎ up‎ to‎ 300‎ μg/g‎ of‎
tumour can be achieved in a brain tumour with Gd-DTPA and gadolinium-
tetraazacyclododecanetetraacetic acid (Gd-DOTA) contrast agents and up to 800 
μg/g‎ of‎ bone‎ tumour‎with‎ gadolinium-ethylene diamine tetramethylphosphonate 
(Gd-EDTMP) [58].  
The total dose rates from‎ 1000‎ μg/g‎ of‎ Gd‎ in‎ tumour‎ were‎ 2‎ Gy/hr‎ of‎
neutrons, 5.5 Gy/hr of gamma rays while from the electrons it was 5 Gy/hr [59-
61].  
Monte Carlo calculations such as Monte Carlo N-Particle code (MCNP4B) 
show that Gd NCT provides a high tumour dose. Also, it was used to calculate the 
total dose distribution from neutrons and prompt gamma emissions for Gd NCT of 
the brain tumours [62, 63].  
In early work, the Gd concentration in rare earth ores was determined, 
using capture gamma rays, from 10-100 mg of each ore sample using a thermal 
neutron flux of 10
8
 n/cm
2
 s [64].  
Gadolinium appears to be a promising alternative to boron as an NCT 
agent. It has distinct advantages over other types of treatment, where healthy 
tissue may receive significant doses.  
In this technique, neutrons from a 
252
Cf source are slowed down by water 
to become thermal neutrons then they incident on the tumour vessel inside the 
head phantom. Following‎the‎neutron‎capture‎(n,‎γ)‎reaction,‎emitted‎gamma‎rays‎
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are measured by an HPGe detector and the associated electronics. The intensity of 
the characteristic gamma ray is proportional to the concentration of the Gd.  
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2.2 Experimental  
2.2.1 Detector System 
The first detector used was a portable HPGe detector, with a relative 
efficiency of 20% (Canberra, USA). The genie PC multichannel analyser (MCA) 
programme supplied by Canberra comprises a power supply, a spectroscopy 
amplifier and a Pentium computer with a special card and software. The MCA had 
8192 channels. The second detector was a standard Tennelec HPGe coaxial 
detector, a vertical type with a relative efficiency of 20% and high energy 
resolution (Tennelec INC, Oak Ridge-USA). The HPGe detectors were supplied 
with a liquid nitrogen Dewar, and a preamplifier/electronics package which was 
connected to a single channel analyser, counter/rate meter, computer-based MCA 
board, computer data analysis and storage and display. 
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2.2.2 Radiation Source 
A number of radiation sources were used for both calibration and the 
experiment as shown in Table ‎2.1.  
 
Table  2.1: Different type of isotope sources used for the research. 
 
Source 
 
 
Activity 
 
 
Half-Life 
 
 
γ (keV) 
 
Calibration Date 
 
252 
Cf 1.4 mCi 2.64 year 100.2 September 19, 
2005 
241
Am-Be 3 mCi 458 year 59.54 December 18, 
1981 
137
Cs 0.962‎μCi 30 year  
661.66 
September 01, 
1978 
5‎μCi 30 year September 01, 
1978 
60
Co 1‎μCi 5.3 year 1173.24 
1332.50 
December 18, 
1981 
152
Eu 2.37 kBq 13 year 121.78 December 01, 
1987 
241
Am 1.04‎μCi 462 year 59.54 September 01, 
1978 
*Multi-
Gamma Ray 
contains: 
Total 
activity       
1.13‎μCi 
_  October 14, 2004 
155
Eu 0.116 µCi 4.96 year 86.54 October 14, 2004 
57
Co 0.147 µCi 271.77 day 122.06 October 14, 2004 
133
Sn
 0.305 µCi 1.47 second 1096.20 October 14, 2004 
137
Cs 0.062 µCi 30 year 661.66 October 14, 2004 
54
Mn 0.114 µCi 312.20 day 834.83 October 14, 2004 
65
Zn 0.341 µCi 244.1 day 1115.52 October 14, 2004 
40
K 0.017 µCi 1.2x 10
9
 year 1460.83 October 14, 2004 
* Multi-Gamma Ray Standard where the total activity was 1.13µCi on October 14, 2004 and 
which contains Eu-155(0.116µCi), Co-57(0.147µCi), Sn-133(0.305µCi), Cs-137(0.062µCi), Mn-
54 (0.114µCi), Zn-65(0.341µCi) and K-40(0.017µCi) 
  
 18 
2.2.3 Gadolinium Compounds 
High purity gadolinium fluoride (GdF3) powder was used. Both GdF3 and 
Magnevist did not show clear gamma peaks because of the low intensity of 
thermal neutrons (the calculated flux is shown on page 25-28). Magnevist contrast 
medium was also used where the active substance is gadopentetic acid and it is 
provided as dimeglumine salt (1 ml of aqueous solution containing 469 mg of 
gadopentetic acid, dimeglumine salt corresponding to 78.63 mg of Gd). The GdF3 
powder and the Magnevist were exposed to the neutron source to activate the Gd. 
 
2.2.4 Other Detectors  
1. Cylindrical boron trifluoride (BF3) neutron proportional counters, LND 
2022 (LND Inc, Oceanside, New York, USA) for slow neutron 
measurement[65]. 
2. Telescope ionisation chamber detector to measure exposure dose, 
TELETECTOR 6112B, 4 meters long (Automation und Messtechnik, 
Ladenberg, Germany) for gamma dose measurements (Figure ‎2.1)[66]. 
3. Neutron monitors, type NM2B, for neutron dose measurements (NE 
Technology, United Kingdom) (Figure ‎2.2)[67]. 
 
2.2.5 Other Materials 
In addition, the following materials were also used in this study. 
A block of lead, size 10 cm x 20 cm and 5 cm thickness. 
Water containers of different thicknesses to thermalise fast neutrons were used. 
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Figure  2.1: Teletector 6112 B detector[66]. 
 
 
 
 
 
 
Figure  2.2: Neutron dosimeter detector (NM2B), Serial No. 433[67]. 
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2.3 Gamma Ray Energy Calibration 
To calibrate the measurement system (HPGe detector) different types of 
sources were used. Firstly, we utilised a combination of two point sources. 
Cesium-137 source (
137
Cs) and cobalt-60 source (
60
Co) whose activities were 5 
μCi‎and‎1‎μCi‎respectively,‎were‎set‎and‎spectra‎that‎appeared‎from‎the‎two‎point‎
sources were determined. We utilised neutron capture gamma rays for calibration 
as well. A sheet of iron was placed between the neutron source and the HPGe 
detector and was exposed to neutrons from a 1.4 mCi 
252 
Cf source. Capture 
gamma rays emitted from the iron were recorded with a HPGe detector. The 
intensity of gamma rays from each source and material were determined and 
recorded. 
The peak from 
137
Cs was at 662 keV. The 1173 keV and 1332 keV peaks 
for the 
60
Co source, and capture gamma rays of iron 6610 keV, 7121 keV and 
7632 keV peaks, were utilised. These peaks were used in the calibration curve to 
identify the gamma rays of the other elements, particularly Gd atoms, during 
exposure to neutrons. The energy calibration curve, Figure ‎2.3, shows a relevant 
straight line calibration, since we know that the capture gamma ray of Gd atoms is 
located between 780 keV and 6750 keV (Table ‎2.2) [68].   
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Table  2.2: Capture gamma rays energy of Gd atoms. 
 
Channel 
Number 
Known energy of Gd 
capture gamma  rays (keV) 
Measured energy of Gd 
capture gamma ray (keV) 
565 780.1 780.5 
688 897.6 897.4 
736 944.1 943 
909 1107.6 1107.3 
917 1116.5 1114.9 
954 1141.4 1150 
 
 
 
 
Figure  2.3: Energy calibration chart of the HPGe detector. 
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2.4 Procedure to design optimum geometry for Gd experiment 
2.4.1 Gamma ray measured by using ionisation chamber 
The aim was to minimise gamma rays coming from a neutron source, as 
they produce unnecessary counts and saturation in the HPGe detector. The 
distance between the neutron source and the detector was adjusted to be 40 cm 
and then 15 cm of lead thickness was placed between the source and the detector 
to reduce the gamma rays coming directly from the neutron source. The 
background was measured using a telescope gamma detector that measures 
gamma dose rates. It was found to be 0.04 mR/hr. The dose rates were taken also 
with the water containers in front and behind the neutron source to slow down fast 
neutrons, as slow neutrons have a higher cross section for interaction. Because 
water backscatters gamma rays, the increase in quantity of water increased the 
gamma exposure. The average dose rate was 2.44 mR/hr (Figure ‎2.4). Data were 
then recorded and analysed. 
 
 
 
 
 
 
 
 
 
 
 23 
 
 
 
 
2.44
1.9
0.8
1.24
0
0.5
1
1.5
2
2.5
3
6 inch of lead thickness +
water thickness  in front and
behind of source
6 inch of lead thickness +
water thickness in front and
behind of source and
surrounding BF3 counter
6 inch of lead thickness +
water thickness
surrounding all setup
6 inch of lead thickness +
water thickness
surrounding all setup plus 4
small cubes of water above
the lead in front of the
source
Type of experiment
G
a
m
m
a
 d
o
se
 r
a
te
 (
m
R
/h
r)
 
Figure  2.4: Gamma rays measured by using ionisation chamber to design 
optimum geometry for neutron capture experiment.  
 
 
 
 
 
 
 
 
 
 
 24 
2.4.2 Neutron flux measured by using neutron proportional counters 
In this procedure we measured slow neutrons that reached the target 
tumour. Slower neutrons were obtained by increasing the volume of the water 
moderator. The boron trifluoride proportional counter is a sensitive thermal 
neutron detector. This BF3 counter was placed 40 cm from the neutron source and 
then 15 cm of lead thickness was placed between the source and the BF3 counter. 
The exposure time was chosen to be real time and set for 10 minutes. The count 
rate of the first reading was taken with the water in front and behind the neutron 
source and showed 81,098 counts per second. As the thickness of water 
surrounding the setup increased, the count rate increased. Counts rate readings  
taken with increased water by using the BF3 detector are shown in  
Table ‎2.3. The highest counts rate was 237,989 counts per second. Counts 
rate data were recorded and analysed. These count rates are proportional to 
thermal neutron flux; they are not the flux. 
 
 
Table  2.3: Slow neutron flux measured by using the BF3 counter in an experiment 
to design the optimum geometry for the neutron capture experiment.  
 
Type of experiment Counts per second  
6 inch of lead thickness + Water thickness  in front and 
back of source 
81098 
6 inch of lead thickness + Water thickness in front and 
back of source and surrounding BF3 
 
204730 
6 inch of lead thickness + Water thickness in front and 
back of source and surrounding all geometry 
 
233738 
6 inch of lead thickness + Water thickness in front and 
back of source and surrounding all geometry & 4 small 
cubes of water above the lead in front of the source 
 
237989 
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2.5 Results and Discussion 
The objective, of studying Gd concentration analysis in the brain phantom 
by NCT, was to develop a technique that measures the amount of Gd and the 
neutron reaction rate, at the same time as a patient is exposed to the neutrons 
emitted by a 1.4 mCi 
252
Cf source. It was intended to measure gamma ray 
emission following neutron capture during the irradiation process. However, 
because the gamma peak observed from the Gd sample in the HPGe detector was 
very weak, it took a long time to accumulate.  A tremendous amount of work was 
done to improve the geometry of the neutron capture experiment shown in Figure 
‎2.5. First we had to reduce, as much as possible, the gamma rays coming directly 
from the source that dominated the spectrum.  We decreased the gamma ray 
counts using a telescope detector (see Figure ‎2.4). Secondly, the slow neutron flux 
had to be increased. By increasing moderation we could increase the flux of slow 
neutrons and that was measured by the BF3 neutron proportional counters.   
With this "enhanced" flux, the Gd peaks were still very small. We 
attempted to use another non-portable germanium detector (coaxial germanium 
detector) to increase the detection efficiency. At this point, we could expose the 
target materials such as boron-10 and Gd, to the neutron source and were 
successful in finding the capture gamma rays of 478 keV from the  boron-10 (see 
Figure ‎2.6), but Gd was still at the smaller end of being measurable. The peak 
height was slightly above background and was falling within the standard 
deviation of the background. 
An experiment was done using Magnevist contrast medium, which 
contained Gd, in which we exposed 160 ml of Magnevist (1 ml of aqueous 
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solution containing 469 mg of gadopentetic acid, dimeglumine salt corresponding 
to 78.63 mg of Gd) for 47 hours. The peak was still not high enough (Figure ‎2.7). 
As in any neutron capture gamma ray analysis, there are large number of gamma 
peaks that were coming from all surrounding materials as well as from the capture 
gamma ray in the HPGe detector. Peaks from lead, aluminium, iron,  concrete etc 
are usually found. Accordingly it is very difficult to analyze the whole spectrum. 
The very large peak found at 2.22 MeV is that of hydrogen neutron capture; there 
was large amount of water surrounding the detector used for neutron 
thermalization. 
The method can be successful only if the neutron flux is high. In our work, 
it took too long time to collect reasonable counts. This is not a very successful 
practical approach.   
To explain the weakness of the counts under the peak that was obtained 
from the experimental, we calculated the effect of neutron attenuation from the 
source to the sample in the experiment.  
Attenuation of neutrons in the system before reaching the sample that 
included the effect of the inverse square law, attenuation and scattering in lead 
and attenuation in water were obtained by  
 

 
S
4r2
e(aPbd1 )e(sPb d1 )e(awd2 )
  (3) 
Where, in Eq. (3) above, φ  is the neutron intensity, and S  is the 252Cf 
neutron source strength.  For our measurements, we used S =2.5x10
6
  n/s. the data 
were provided by Nuclear Engineering department at King Abdulaziz University.  
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r is the distance from source to the target material (35 cm for our measurements). 
d1 and d2 are the thicknesses of lead and water, respectively.   We used 15 cm of 
lead‎and‎20‎cm‎of‎water.‎‎∑aPb,‎∑sPb,‎and‎∑aw are the macroscopic cross sections.  
The aPb is for the absorption cross section of lead (0.0056 cm
-1
), the sPb is for  
the scattering cross section of lead (0.3757 cm
-1
) and the aw is for the absorption 
cross section of water (0.0222 cm
-1
) [69].  
 
In Eq. (3), we neglected attenuation due to scattering in water as the flux 
of neutrons was compensated by thermalisation.   Using the values given above, 
we can obtain,‎φ = 0.342 n/cm2 s. 
The attenuation, , of neutrons in the Magnevist agent (C28H54GdN5O20) 
was obtained by the equation:  

  e
(aMgnd )
    (4) 
 
Where‎∑aMgn is the macroscopic absorption cross section of Magnevist 
whose density is 1.2 g cm
-3
. d is the thickness of the Magnevist and we used 0.5 
mm and 1.0 mm thicknesses.  Furthermore, we can write 

aMgn  N      (5) 
Where N  is the number of Gd molecules per cm
3,‎and‎σ‎‎is‎the‎absorption‎cross‎
section of Gd (49000 barn) 
Using these values we obtain attenuations of 0.15 and 0.023 for 0.5 mm 
and 1.0 mm thickness of Magnevist, respectively.   
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The neutron intensity after 1mm of Magnevist will be  
(0.342 n/cm
2
. s) x (0.023 n/s) = 7.87x10
-3
 n/cm
2
.s  
Accordingly most of the neutrons are absorbed in the first 1 mm of the 
Magnevist contrast medium; therefore the reaction volume is very small.  
 
The neutron spectrum is a fission spectrum. If only 10% of the neutrons 
are thermal neutrons, then the slow neutron flux at the sample position will reduce 
the intensity even much below the above number. 
 
It is clear that the slow neutron flux is very low at the magnevist agent and 
most of slow neutrons are absorbed in 1 mm of Magnevist. Therefore, additional 
Gd will not be useful for increasing count. 
 
The 47 hr (1.69x10
5
 sec.), collection time will give a neutron fluence of  
1.69x10
5
 sec x 7.87x10
-3
 n/cm
2
.s = 1.33x10
3
  n/cm
2
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Figure  2.5: Lateral view of schematic that represents the optimum geometry to 
measure Gd concentration..  
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Figure  2.6: Neutron capture gamma ray spectrum of boron. 
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Figure  2.7: Neutron capture gamma ray spectrum of Gd. 
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 CHAPTER 3 
MATERIALS AND METHODS OF THE GADOLINIUM 
CONCENTRATION ANALYSIS 
 
 
3.1 Experimental Materials 
The experimental materials consisted of 
•‎The‎radiosurgery verification head phantom 
•‎The‎alignment‎system 
•‎The‎detector 
•‎Radiation‎source 
Each of these will be discussed in more detail below.  
3.1.1 The Radiosurgery Verification Head Phantom (RSVP) 
The radiosurgery verification head phantom (RSVP) is placed on a table in 
the supine position, facing up to enable the correct simulation of patient-imaging 
and dose assessment. The shell of the RSVP consists of 3.18 mm thick cellulose 
acetate butyrate (CAB), a transparent plastic selected for its strength and low 
water absorption. The shell is fixed to a durable polycarbonate end plate, which is 
connected to a cover plate and an assembly that enables the tumour vessel to be 
turned around and processed. The head case of the radiosurgery system can be 
screwed directly onto the CAB plastic [70].  
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The RSVP consists of a tumour vessel, position rod, cover plate O-ring, 
rotation ball O-ring, rotation ball, lock bolts for position rod, lock nut for rotation 
ball and cover plate (Figure ‎3.1).  
The position rod was used to hold the tumour vessel by threading it into 
the connector to close the port of the tumour vessel. The position rod was inserted 
into the rotation ball that was used to move the position rod in different directions 
and positions inside the head phantom. 
The lock bolts on the position rod were loosened so as to insert it through 
the rotation ball, until the rod was extended to the desired distance into the head 
phantom. The lock bolts were tightened when the position rod was in the proper 
position. The head phantom was filled with water which is equivalent to the brain 
tissue. The rotation ball, position rod and tumour vessel were reinserted into the 
head phantom and the rotation ball lock nut was fitted loosely on to the phantom. 
The ball was rotated until the tumour vessel was in the desired position and the 
rotation ball lock nut was tightened. The phantom was placed in the face-up 
position to check for any leaks as shown in Figure ‎3.1. 
The RSVP is able to contain spherical hollow tumour vessels whose 
diameters are 1.0 cm, 2.0 cm, and 3.0 cm. It is also able to contain a hollow oval 
tumour vessel whose diameter is 2.0 cm and its length is 4.0 cm (see Figure ‎3.2). 
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Figure  3.1: Components of the radiosurgery verification head phantom. 
1. Tumour vessel  2. Position rod  3. Cover plate O-ring  4. Rotation ball O-ring                 
5. Rotation ball  6. Lock bolts for position rod  7. Lock nut for rotation ball 
8. Cover plate [69].   
 
 
 
 
Figure  3.2: Radiosurgery verification head phantom in an upright position [69]. 
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3.1.2 Alignment System 
To determine the position of the tumour vessel inside the head phantom, a 
measurement system has been created at the University of Canterbury by a 
technician (Figure ‎3.3). The alignment system consists of: a head phantom tumour 
vessel, scale and a laser alignment system. 
The head phantom including a tumour vessel is placed on a custom wood 
platform. Then the position of the tumour vessel, inside the head phantom, was 
determined along two orthogonal axes by a laser pointer that moves along the 
orthogonal axes with mm scales. This system can identify the centre of the tumour 
vessel to ±0.2 mm. The position of the vessel is estimated to be reproducible to ± 
0.5 mm see Figure ‎3.1. The anatomical marker of the tumour vessel was chosen to 
be 5.0 cm above the left lateral of the external auditory meatus (ear) and 1.0 cm 
posterior. 
 
 
Figure  3.3: Alignment of tumour vessel scale with laser beam pointer. 
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3.1.3 X-Ray Detector 
The x-ray detector system consists of a model, XR-100T-CdTe, (cadmium 
telluride) counting system and Genie 2000 PC MCA. The counting system 
consists of x-ray and gamma detectors, preamplifier, and a cooling system (Figure 
‎3.4). The 3 x 3 x 1 mm3 cadmium telluride (CdTe) diode detectors are mounted on 
a thermoelectric cooler. These have an energy resolution <1.2 keV FWHM, at 122 
keV of 
57
Co with a beryllium (Be) window, 250 µm thick [71]. The MCA is 
supplied by Canberra Company USA. It has a comprehensive unit for power 
supply, amplification and a Pentium computer with a special interface card and 
software. The MCA has 8,192 channels. 
 
 
 
Figure  3.4: XR-100T-CdTe detector with power supply and amplifier [70]. 
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3.1.4 Radiation Source 
Americium is a man-made radioactive source which is produced when 
plutonium atoms absorb neutrons in nuclear reactors. Americium-241 has many 
medical and industrial applications and is also used in research. Americium-241 is 
an unstable isotope that emits alpha particles and gamma rays. The 
241
Am source, 
used in this work, had 37 GBq (1 Ci) of activity on February 22, 1989. The half-
life of 
241
Am is about 432.7 years. It produces a 59.5 keV gamma ray with a 
relative probability of 0.357 per disintegration [72]. By using the radioactive 
decay law expressed mathematically as: 
 
                                          At=A0 e
- λt
                          
 
where A0 is the initial quantity of activity, At is the amount of activity left 
after‎time‎t,‎λ‎is‎the‎radioactive‎decay‎constant‎(0.693/T1/2) [73, 74].  
The calculated amount of activity used for this experiment as calculated 
from the equation above was 0.97 Ci (36 GBq). The 
241
Am source is in the form 
of an oxide pressed into a ceramic cylinder with dimension of 0.3 cm in diameter 
and 1 cm in height. The shape of the source is cylindrical and it is a single 
encapsulation made of stainless steel and laser seal welded. 
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3.1.5 Contrast Examination 
Gd DTPA is a contrast agent that produces magnetic effects (the 
commercial name is Magnevist). It is used in combination with MRI to allow 
blood vessels, and internal organs to be seen more clearly.  
''Magnevist Injection is a 0.5-mol/L solution of l-deoxy-l-(methylamino)-
D-glucitol dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-glycinato-
(5"-)-]gadolinate(2-)(2:1) with a molecular weight of 938, an empirical formula of 
C28H54GdN5O20,'' [75].  
Gd-DTPA contains the active substance, gadopentetic acid, and 
dimeglumine salt. One millilitre of aqueous solution contains 469 mg of 
gadopentetic acid, and dimeglumine salt that corresponds to 78.63 mg of Gd. 
Magnetic resonance imaging will be valuable and very effective, when a 
contrast media, such as Magnevist, which has a paramagnetic ion (Gd) that 
increases tissue relaxation rate in that magnetic field. Gadolinium is mixed with 
other chemical metals to reduce the toxicity in its properties. There are several Gd 
based contrast agents available such as: "gadopentetate dimeglumine (Magnevist), 
gadodiamide (Omniscan), gadoteridol (ProHance) and gadoversetamide 
(OptiMARK)". The biological half-lives of these agents are similar, at about half 
an hour. The common side effects of the contrast agent are nausea, headache, 
anaphylactic reaction and vomiting. 
The Food and Drug Administration has approved the usage of specific 
dosage volume of this contrast (0.23 to 0.31) ml/kg for adults; whereas in 
children, the dose is 0.16 ml/kg body weight [76, 77].  
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3.1.6 Other Materials 
In addition, the following materials were also used in this study. 
Densitometer, model 07-443, S/N 107679, Nuclear Associates Division of 
Victoreen Inc (Phoenix, USA). 
Normal saline, 0.9% w/v sodium chloride, intravenous infusion B.P. 
500ml (Na
+
 150 mmole/L, Cl
-
 150 mmole/L). 
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3.2 Experimental Method 
A tremendous amount of work was done to measure Gd concentration and 
to improve the geometry of the experiment to reach the optimum result. The 
purpose was to provide a method for the analysis of the amount of the Gd in the 
brain tumour. Characteristic x-rays of Gd Kα1 = 42.98 keV, induced by a 36 GBq 
(0.97 Ci) 
241
Am source, were emitted and measured. 
The lateral and the vertex positions of the head phantom were selected, to 
measure the concentration of the Gd in different sized of the tumour vessels as 
shown in Figure ‎3.5. Also, the depths of the tumour were measured from the 
surface of the head phantom to the centre of the tumour vessel. These depths 
ranged from 0.5 cm to 5.5 cm between the centre of the tumour and interior wall 
of the head phantom surface. Concentrations from 5.62 to 78.63 mg/ml of Gd in 
the tumour vessel were used and measured.  
Tumour movement inside the head phantom is described by defining the 
sagittal and transverse planes. The sagittal plane is the plane that divides the body 
to the left side and right side, while the transverse plane is the plane which divides 
the body to the superior (top side) and inferior (bottom side).  
In the lateral position, the tumour vessel moves parallel to the transverse 
plane is and is perpendicular to the sagittal plane. In other words, the tumour 
vessel moves from the left to the right side. While in the vertex position, the 
tumour vessel moves parallel to the sagittal plane and is perpendicular to the 
transverse plane or the tumour moves from the top end to the bottom end.  
An analysis of the results provided information concerning those aspects 
of radiotherapy-planning that needed attention.  
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Figure  3.5: Schematic representation of the head phantom contain tumour vessel 
in the lateral position. The source and detector are also shown as a lighter image 
in the vertex position. 
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3.2.1 X-Ray Energy Calibration  
Energy calibration was required to guarantee that the cadmium telluride 
(CdTe) detector was operating correctly to measure the energy of the gamma 
radiation, which was emitted directly from the source and also, the x-ray energy 
that was reflected from the target materials. Therefore to calibrate the 
measurement system (XR-100T-CdTe detector), 500 grams of barium diagnostic 
agent (100 grams contains 95 grams of barium sulphate), providone-iodine U.S.P 
10%, a sheet of cadmium and an iron plate, were used and exposed separately and 
in combination to a 36 GBq 
241
Am source to determine the characteristic x-ray 
(Kα) emission of the materials. Kα x-ray peaks of Fe, Cd, I, Ba, and the direct 
energy of the 
241
Am source in the pulse height distributions are shown 
respectively in Table ‎3.1.  
These were used to identify the energy of the characteristics x-ray (Kα) of 
each element and to compare it with the characteristics x-ray (Kα) of the literature 
of the same element. Figure ‎3.6 and Figure ‎3.7 show the energies of the 
characteristic x-rays that were measured. They were really identical to the energy 
of the characteristics x-ray from the literature studied [78-80]. Also, the 
background count was measured by filling the head phantom, including a tumour, 
with water that simulated the brain tissue, which showed zero count. The positions 
of the tumour inside the head phantom were determined and adjusted by the 
tumour scale and the laser alignment system that were made for this purpose in 
physics department workshop. 
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Table  3.1: Characteristics X-rays energy calibration of spectroscopy system using 
known element. 
 
Calibration 
Element 
Channel 
Number 
Kα (keV) 
(Literature)  
Kα (keV) 
 (Measured)           
Iron 465 6.40 6.4 
Cadmium 2330 23.17 23.1 
Iodine 2941 28.61 28.5 
Barium 3343 32.19 32.1 
Americium 6415 59.54 59.6 
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Figure  3.6: Energy calibration of spectroscopy system using known 
characteristics x-ray. 
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Figure  3.7: Energy calibration curve of XR-100T-CdTe detector. 
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3.3 Procedure for Measuring Gd Concentration 
The concentration of Gd (mg/ml) and the total amount of Gd (mass of Gd 
in Magnevist contrast medium (mg)) in the tumour vessel inside the head phantom 
were calculated. The procedure included several stages which are explained 
sequentially.  First, the level of the table and the head phantom was adjusted using 
a spirit level. An 
241
Am source beam faced the head phantom which included the 
tumour vessel. The position of the XR 100T CdTe detector with a standard 3.81 
cm extender collimator was positioned on the top of the table parallel to the 
241
Am 
source and toward the tumour vessel. The position of the tumour vessel inside the 
head phantom was adjusted by using the pointer laser which was placed in the 
collimator of the detector, before tumour exposure to gamma radiation. The XR 
100T detector was connected to the Genie 2000 PC MCA. The distance from the 
surface of the head phantom to the 
241
Am source was adjusted to be 6.0 cm, 8.3 
cm to the detector and the exposure time was chosen to be live time and set for 30 
minutes, to obtain the maximum count collection. 
The different size and shape of the tumour vessels were selected for 
exposure. These sizes were 1.0 cm, 2.0 cm, 3.0 cm, 2.0 x 4.0 cm and the shapes 
were spherical and oval. The entire tumour vessel was hollow to enable it to be 
filled with contrast medium. Also, the depths of the tumour were measured from 
the surface of the head phantom to the centre of the tumour vessel. These depths 
ranged from 0.5 cm to 5.5 cm between the centre of the tumour and interior wall 
of the head phantom surface. 
Different concentrations of the Gd were injected into the tumour vessel 
through the tumour port at the base of the position rod connector (see Figure ‎3.1). 
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The maximum value of the Gd concentration was limited by its concentration in 
the Gd-DTPA. Concentrations from 5.62 to 78.63 mg/ml of Gd in the tumour 
vessel were used and measured. Checking for any leaks in the tumour vessel was 
performed after each filling. 
The position rod was threaded into the connector to close the port, and the 
position rod was inserted into the rotation ball. The lock bolts on the position rod 
were loosened to insert it through the rotation ball until the rod extended to the 
desired distance into the head phantom. The lock bolts were tightened when the 
position rod was in the proper position. The head phantom was filled with water 
which is equivalent to the brain tissue. The rotation ball, position rod, and tumour 
vessel were reinserted into the head phantom and the rotation ball lock nut was 
fitted loosely on to the phantom. The ball was rotated until the tumour vessel was 
in the desired position and the rotation ball lock nut was tightened. Again there 
was a check for any leaks in the head phantom. 
The position of the tumour vessel was adjusted inside the head phantom by 
using the tumour scale and the laser alignment system (see Figure ‎3.3) where the 
anatomical marker of the tumour vessel inside the head phantom was chosen to be 
5.0 cm above the left lateral of the external auditory meatus (ear) and 1.0 cm 
posterior. Lateral and vertex positions were selected to measure the concentration 
of the Gd in the tumour vessel. In the lateral position the head phantom was 
placed in the supine position on the table (facing up) with the left lateral of the 
external auditory meatus (left ear) toward the 
241
Am source and XR 100T CdTe 
detector (see Figure ‎3.5). In the vertex position, the head phantom, faced up and 
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the vertex landmark (top side) was placed toward both the source and the detector. 
An exposure was made for 30 minutes and the data collected and analysed. 
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 CHAPTER 4 
 
RESULTS AND DISCUSSIONS 
 
This chapter presents the results and the discussion in three sections 
describing the dependence of the total count of the characteristics x-ray on the 
concentration of Gd (mg/ml), the total amount of Gd (mg); tumour depth, the 
tumour size and the positioning of the head phantom. The first section provides an 
introduction; the second section presents the results; the third section is a 
discussion of the results. 
 
4.1 Introduction 
The head phantom, containing Gd contrast medium in the tumour vessel, 
was placed in front of an 
241
Am source. The counts of the characteristic x-ray in 
the lateral and vertex positions of the head phantom were taken. Almost adjacent 
to the source, the x-ray detector was positioned as shown in Figure ‎4.2 and Figure 
‎4.22. A gamma ray from the source penetrated the head phantom and interacted 
with the Gd atoms inside the tumour vessel. Following the interaction, a 
characteristic x-rays of Gd were emitted in all directions. some reached the CdTe 
detector where they were detected and measured. The energy of the characteristics 
x-ray emitted was measured at 42.98 keV. The detector also measured scattered 
radiation. The energy of the scattered photons was calculated by using the 
following equation for Compton scattering: 
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
E 
E
1 (E /m0c
2)(1 cos)                           (6)            
Where E is the energy of the incident photon, E' the energy of the scattered 
photons, m0c
2
 is the rest mass energy of electron‎(511‎keV),‎and‎θ‎is‎the‎scattering 
angle for the scattered photons [81, 82]. At 138
 
degrees of scattering, between the 
incident radiation from the source and the scattered radiation reaching the 
detector, the scattered photons give a broad Compton peak at 49 keV.  
The characteristic x-ray peak of the Gd atoms (42.98 keV) was clear and 
easily separated from the scattered photon peak (49 keV) as shown in Figure ‎4.1. 
 
 
Figure  4.1: Spectrum of the characteristic x-rays of Gd obtained from a 3 cm 
diameter tumour vessel, which contained 50.55 mg/ml of Gd at a depth of 1.0 cm 
in the lateral position. 
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4.2 Results 
This section presents the results of the dependence of the total counts on 
the Gd concentration. The measurements were taken for the phantom head in the 
lateral and vertex positions. For each of the positions, the dependence of the total 
counts on the Gd concentration was measured regarding the tumour size, tumour 
depth and the presence of water inside the head phantom. The following two 
subsections present the results of each phantom position. 
4.2.1 Measurements of Gd concentration on lateral position: 
The tumour containing the contrast agent (Magnevist) was placed at 
different depths inside a head phantom in the lateral position in front of the CdTe 
detector and the 
241
Am source, for measurements, as described in chapter 3 
section 3.3. A photograph of the experimental setup for the lateral position is 
presented in Figure ‎4.2. The results of the dependence of the total counts of the 
Gd characteristics x-ray for 30 minutes counting time on Gd concentration as a 
function of the tumour depth are shown in Figure ‎4.3 to Figure ‎4.12 as explained 
below. The results of the experiments show that the required Gd concentrations 
were obtained by using the correct contrast agent (Magnevist) to the water ratio. 
The purpose of the water ratio is to achieve optimum homogeneous distribution of 
Magnevist contrast medium inside the tumour vessel. 
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Figure ‎4.2: Head phantom containing the tumour vessel in the lateral position. 
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The dependence of the total count on the Gd concentration as a function of 
the tumour depth for the tumours of the following sizes: 1.0 cm, 2.0 cm, 3.0 cm, 
and 2.0 x 4.0 cm is shown in Figure ‎4.3 to Figure ‎4.6. For each tumour, data are 
presented for the tumour with water and without water. However, data are 
presented for the 1.0 cm tumour only without water as shown in Figure ‎4.3. As the 
diameter of the tumour was small, it was difficult to measure the characteristic x-
rays that were emitted from the tumour containing Gd in the head phantom filled 
with water to mimic biological tissue. So, all the experiments for the 1.0 cm 
tumour were conducted in an empty head phantom. All the Figures (Figure ‎4.3 to 
Figure ‎4.6) show that the total count increased as the Gd concentration increased. 
They also show that the total count decreased as the tumour depth increased. 
Comparisons of the dependence of the total counts on the Gd 
concentration for the head phantom with and without water are shown in Figure 
‎4.3 to Figure ‎4.6. for example, the measurements that were taken at depths of 1.0 
cm and 2.0 cm for a tumour vessel size 2.0 cm; at depths of 1.5 cm and 4.5 cm for 
a 3.0 cm diameter tumour; and at depths of 1.0 cm and 3.5 cm for the 2.0 x 4.0 cm 
tumour, show the total counts increase as the concentration increases and they are 
higher for the phantom head without water for each tumour depth as discussed in 
the next section. 
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Figure  4.3: Counts versus concentration of Gd at different depths for a 1.0 cm 
diameter tumour inside a head phantom in the lateral position. The lines are drawn 
to guide the eye. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
 
 
 
 
 
 
0
100000
200000
300000
400000
500000
20 30 40 50 60 70 80
Concentration of Gadolinium (mg/ml)
T
o
ta
l c
o
u
n
ts
 f
o
r 
3
0
m
in
1cm depth Water 1.5cm depth Water
2cm depth Water 2.5cm depth Water
1cm depth Empty 1.5cm depth Empty
2cm depth Empty 2.5cm depth Empty
3cm depth Empty 3.5cm depth Empty
4cm depth Empty 4.5cm depth Empty
5cm depth Empty 5.5cm depth Empty
 
Figure  4.4: Counts versus concentration of Gd at different depths for a 2.0 cm 
diameter tumour inside a head phantom with and without water in the lateral 
position. The lines are drawn to guide the eye.  
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Figure  4.5: Counts versus concentration of Gd at different depths for a 3.0 cm 
diameter tumour inside a head phantom with and without water in the lateral 
position.  The lines are drawn to guide the eye. 
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Figure  4.6: Counts versus concentration of Gd at different depths for a 2.0 x 4.0 
cm diameter tumour inside a head phantom with and without water in the lateral 
position.  The lines are drawn to guide the eye.  
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The dependence of the total count on the tumour depth, as a function of 
the Gd concentration for the tumours of the sizes of 1.0 cm, 2.0 cm, 3.0 cm, and 
2.0 x 4.0 cm are shown in Figure ‎4.7 to Figure ‎4.10. The depth of the tumour was 
measured from the surface of the head phantom to the centre of the tumour vessel. 
These depths were 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0 and 5.5 cm. Figures 
are presented for each tumour: one with water and one without (except for the 
tumour size 1.0 cm) as explained above.  
These figures show that the total counts decreased as the tumour depth 
increased inside the head phantom. The figures also show that the total count 
increased, as the Gd concentration increased. 
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Figure  4.7: Counts versus tumour vessel depth at different concentrations of Gd 
for a 1.0 cm diameter tumour, inside head phantom, in the lateral position. 
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Figure  4.8: Counts versus tumour vessel depth at different concentrations of Gd 
for a 2.0 cm diameter tumour inside a head phantom with and without water in the 
lateral position. 
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Figure  4.9: Counts versus tumour vessel depth at different concentrations of Gd 
for a 3.0 cm diameter tumour inside a head phantom with and without water in the 
lateral position. 
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Figure  4.10: Counts versus tumour vessel depth at different concentrations of Gd 
for a 2.0 x 4.0 cm diameter tumour inside a head phantom with and without water 
in the lateral position. 
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The relationship between the measured attenuation of the water in the 
skull using the different Gd concentrations (mg/ml) and the different tumour 
depths are shown in Figure ‎4.11.  The line is the predicted attenuation for the 
known scattering and absorption of water.  The incident radiation of 59.5 keV 
from the source and the emitted characteristic x-ray of 42.98 keV undergo 
attenuation by the water inside the head phantom in the lateral position. The 
attenuation of the incoming 59.5 keV gamma ray is given by exp[-µ(59.5 keV) x], 
while the attenuation due to the emitted characteristic x-ray of 42.98 keV is exp[-
µ(42.98 keV) x'], where x and x' are the distance of the incident radiation and 
emitted characteristic x-ray respectively, that travels though the water. 
The correlation between the experimentally determined attenuation of and 
the calculated attenuation was observed. 
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Figure ‎4.11: Calculated attenuation compared with measured attenuation at 
different distance (cm) and different concentrations of Gd on a 2.0 cm, 3.0 cm and 
2.0 x 4.0 cm diameter tumour, inside the head phantom water, in the lateral 
position. 
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Figure 4.12 shows the total counts versus the concentration of Gd, 
obtained from the tumour size of 1.0 cm, 2.0 cm, 3.0 cm and 2.0 x 4.0 cm at a 
depth of 1.5 cm in the head phantom without water, in the lateral position. These 
are drawn in order to show the effect of the tumour size on counts. Clearly, an 
effect of the tumour size is observed, where increased size of the tumour vessel 
lead to increases in the total counts. For the 1 cm tumour, the counts appear to 
increase linearly with concentration.  For each of the larger size tumours, the 
counts start to increase almost linearly with the amount of Gd for the smallest 
concentration and then it seems to tend towards a saturation (or the data are non-
linear and seem to approach a plateau).  This possibly indicates reabsorption of 
emitted rays at the higher concentrations of Gd. The highest counts were obtained 
from the 3.0 cm diameter of the tumour size. In this case the tumour vessel 
exposed to the gamma beams has the largest volume and cross sectional area 
providing higher probability for interaction. 
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Figure  4.12: Counts versus concentration of Gd in different tumour sizes in the 
head phantom without water at a depth of 1.5 cm for all sizes in the lateral 
position. 
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To obtain the size and the shape of the tumour by a radiographic method, a 
general x-ray machine with radiograph film has been used. Radiographic images 
are shown in Figure ‎4.13 to Figure ‎4.20. In this case the tumour of 3 cm diameter 
containing the Gd agent was placed at a 1.5 cm depth inside the head phantom 
containing water. The left lateral of the head phantom was put in contact with the 
table and the median Sagittal plane was parallel to the film, while the x-ray beam 
was perpendicular to the film and sagittal plane. The central ray was centred to the 
right external auditory meatus. Radiographic exposure factors for the experiments 
were fixed at 73 kVp, 20 mAs, with the source film distance of 105 cm, and the 
cassette size was a 24 cm x 30 cm. After the radiographic films were exposed 
using a conventional x-ray machine (General Eelectric, USA), x-ray films were 
developed which involved automatic chemical processing where the 
concentrations of the chemical and the temperature were higher than the usual 
values used in routine processing in radiology department (Kodak film 
processing, Japan). These radiographic films showed the 3.0 cm tumour image in 
the lateral position with Gd concentrations of 0.56, 2.81, 5.62, 16.85, 28.08, 
39.32, 50.55 and 78.63 mg/ml. The presence of the Gd compound in the tumour 
vessel inside the head phantom was clearly seen on the radiographic film. The 
outline of the tumour vessel was apparent.  
The differences of optical density in the x-ray films, as shown in Figure 
‎4.21, were obtained when the densities from the centre of the tumour vessels were 
subtracted from the densities of the darkest point on the x-ray films by using a 
Victoreen densitometer (Phoenix, USA). That showed that the noise was 
increased with low concentration of the Gd. Because radiographic film may be 
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subjected to different chemical processes where the darkness will be affected, 
these measurements would be very hard to be quantitative. Accordingly it is 
difficult to use the film for measuring Gd concentrations.  
The main use of radiographic film is to show the size and shape of the 
tumour. Based on that the appropriate shape of concentration can be selected.  
It is obvious that at low concentration, the noise will be much large as seen 
from the point on the curve, at low concentration.  
The value at 5 mg/ml showed a significant dip. The non-uniformity of the 
chemical processing across the film can be one reason of this dip. This is not 
expected to be normal trend of the curve. It is considered an error point and 
indicative of the amount of scatter that one experiences in the data when the 
density of film is used to try and quantify concentrations.    
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Figure  4.13: Radiograph of the 3 cm tumour vessel which contains 0.56 mg/ml of 
Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
 
 
Figure  4.14: Radiograph of the 3 cm tumour vessel which contains 2.81 mg/ml of 
Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
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Figure  4.15: Radiograph of the 3 cm tumour vessel which contains 5.62 mg/ml of 
Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
 
Figure  4.16: Radiograph of the 3 cm tumour vessel which contains 16.85 mg/ml 
of Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
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Figure  4.17: Radiograph of the 3 cm tumour vessel which contains 28.08 mg/ml 
of Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
 
Figure  4.18: Radiograph of the 3 cm tumour vessel which contains 39.32 mg/ml 
of Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
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Figure  4.19: Radiograph of the 3 cm tumour vessel which contains 50.55 mg/ml 
of Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
 
Figure  4.20: Radiograph of the 3 cm tumour vessel which contains 78.63 mg/ml 
of Gd concentration inside the head phantom taken at 73KVp, 20 mAs, and at 105 
cm SFD. 
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Figure  4.21: Difference of optical density versus concentration of Gd in a 3.0 cm 
diameter tumour vessel, at 1.5 cm depth inside the head phantom, in the lateral 
position. 
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4.2.2 Measurements of Gd concentration on vertex position 
All of the measurements in this section were taken for the head phantom in 
the vertex position (see Figure ‎4.22) as described in chapter 3 section 3.3. The 
results for the dependence of the total counts of Gd characteristic x-rays (for 30 
min) on Gd concentration as a function of the tumour depth are plotted in Figure 
‎4.23 to Figure ‎4.32 as explained below. 
Figure ‎4.23 to Figure ‎4.26 show the dependence of the total count on the 
Gd concentration as a function of the tumour depth for tumour sizes of 1.0 cm, 2.0 
cm, 3.0 cm, and 2.0 x 4.0 cm. For each tumour, two sets of data are presented 
(with and without water) except for the 1.0 cm tumour (i.e., without water) in 
Figure ‎4.23 as explained above. All figures (Figure ‎4.23 to Figure ‎4.26) show that 
the total count increased as the concentration increased and the total count 
decreased as the tumour depth increased. 
In figure 2.24 it is observed that at the region when the tumour was in 
contact with skull (1 cm depth) higher counts of empty head was obtained. When 
the tumour is in contact with skull there is insignificant absorption of incident ray 
in water when head is filled with water. At the same time of the incident radiation 
that interact with water surrounding the tumour scatter in to the tumour. The 
scatter radiation still has energy above the excitation energy of Gd. Accordingly 
the excitation in Gd and emitted characteristics x-rays are increased compared 
with empty head.  
Figure ‎4.27 to Figure ‎4.30 shows the dependence of the total counts on the 
tumour depth as a function of the Gd concentration for the previous results 
(Figure ‎4.23 - Figure ‎4.26) with and without water. The figures show that the total 
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counts decreased as the tumour depth increased and Gd concentration increased. 
The decrease of counts with depth is not expected to follow exactly the inverse 
square low because the source is an extended source whose dimension is 
comparable to the distance from the detector. The inverse square can apply only if 
the source is a point source, which is not the case here.  
The measurements that were taken at depths of 1.0 cm and 2.0 cm for 
tumour sizes of 2.0 cm; at depths of 1.5 cm and 4.5 cm for the 3.0 cm tumour; and 
at depths of 2.0 cm and 4.0 cm for the 2.0 x 4.0 cm tumour. They show that the 
total counts were higher for the phantom head without water for each tumour 
depth. 
Figure ‎4.31 shows the attenuation versus distance (cm) at different 
concentrations of Gd for the X-ray beams that undergo attenuation in the water 
inside the head phantom, in the vertex position. These figures clearly show a good 
correlation between the experimental and the calculated attenuation. 
Figure  4.32 showed the total counts from the tumours of 1.0 cm, 2.0 cm, 
3.0 cm and 2.0 x 4.0 cm at a depth 2.0 cm in the head phantom without water in 
the vertex position. In these Figures, the bigger the tumour, the greater the amount 
of Gd and the larger the signal detected by the detector. 
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Figure  4.22: Head phantom containing tumour vessel in the vertex position. 
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Figure  4.23: Counts versus concentrations of Gd at different depths for a 1.0 cm 
diameter tumour, inside the head phantom in the vertex position. 
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Figure  4.24: Counts versus concentrations of Gd at different depths for a 2.0 cm 
diameter tumour, inside the head phantom with and without water, in the vertex 
position. 
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Figure  4.25: Counts versus concentrations of Gd at different depths for a 3.0 cm 
diameter tumour, inside the head phantom with and without water, in the vertex 
position. 
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Figure  4.26: Counts versus concentrations of Gd at different depths for a 2.0 x 
4.0 cm diameter tumour, inside the head phantom with and without water, in the 
vertex position. 
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Figure  4.27: Counts versus tumour vessel depth at different concentrations of Gd 
for a 1.0 cm diameter tumour, inside the head phantom in the vertex position. 
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Figure  4.28: Counts versus tumour vessel depth at different concentrations of Gd 
for a 2.0 cm diameter tumour, inside the head phantom with and without water, in 
the vertex position. 
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Figure  4.29: Counts versus tumour vessel depth at different concentrations of Gd 
for a 3.0 cm diameter tumour, inside the head phantom with and without water, in 
the vertex position. 
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Figure  4.30: Counts versus tumour vessel depth at different concentrations of Gd 
for a 2.0 x 4.0 cm diameter tumour, inside the head phantom with and without 
water, in the vertex position. 
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Figure  4.31: Calculated attenuation compared with measured attenuation at 
different distance (cm) and different concentrations of Gd for a 2.0 cm, 3.0 cm 
and 2.0 x 4.0 cm diameter tumour, inside the head phantom, in the vertex position. 
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Figure  4.32: Counts versus total amount of Gd in different tumour sizes in the 
head phantom without water, at a depth of 2.0 cm, for all sizes in the vertex 
position. 
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4.3 Discussion 
The aim of this research was to develop a technique that measures the 
amount of Gd in the brain tumour vessel at the same time as a patient is exposed 
to neutrons or during external beam radiotherapy planning in a NCT treatment. 
An X-ray fluorescence technique was used. Gadolinium atoms in the tumour 
vessel were excited by a 36 GBq (0.97 Ci) 
241
Am source. A cadmium telluride 
detector measured emitted characteristic fluorescence radiation. The energy of the 
incident radiation (59.5 keV) was slightly greater than the binding energy of the 
Gd atom (50.23 keV), therefore the maximum effectiveness of the characteristic 
x-ray excitation was achieved.     
During this process K shell electrons were ejected with a kinetic energy 
equal to the difference between the incident photon energy and the K shell 
binding energy. Electrons from the L shell immediately occupied the vacancy in 
the K shell. This electron transition was accompanied by the emission of a 
fluorescence x-ray whose energy was equal to the difference in binding energy of 
the electron between its original shell and its new shell as shown in Equation 3.  
Ex-ray (Kα) = EB (K) – EB (L)                 (3) 
Ex-ray (Kα) is the characteristic x-ray energy of the Kα, EB (K) is the 
electron binding energy of the K shell, and EB (L) is the electron binding energy 
of the L shell. We mention that the fluorescence yield of the K shell is 93.5% [83, 
84]. 
 
 86 
As K shell electrons of the Gd atoms have a binding energy of 50.23 keV, 
and L shell electrons are bound by 7.25 keV, the characteristic x-ray emitted has 
an energy of:   
50.23 keV - 7.25 keV = 42.98 keV 
According to this result, the characteristic emission of Gd is 42.98 keV photons. 
The concentration of Gd in the tumour vessel was obtained by determining the 
region of interest area under the curve of the x-ray peak. The instrument 
calculated the net area automatically, where the background counts were 
subtracted from the integral counts. So, the observed count rate from x-ray peaks 
of the Gd was dependent on the amount of Gd present in the brain tumour vessel.  
Magnevist is a well known agent for MRI tumour imaging and can be 
readily taken by the body. Magnevist contains Gd; this element has the highest 
cross section for neutrons and can be readily used for Gd NCT. After neutron 
absorption, conversion electrons, Auger electrons and characteristic x-rays are 
emitted that dissipate energy in the tumour, killing tumour cells. Because of the 
neutrons interaction with Gd nuclei the energy deposited in the dose, depends on 
the amount of the Gd atoms present. Accordingly, the total number of Gd atoms 
and the Gd concentration are determine required the dose.      
Different sizes of the tumour vessel containing different concentrations of 
the contrast agent (Magnevist), were placed at different depths inside a head 
phantom at the lateral and the vertex position, in front of the detector and source 
for measurements. The tumours with spherical shapes (diameters of 1.0 cm, 2.0 
cm and 3.0 cm) and oval shape (two diameters of 2.0 x 4.0 cm) were applied and 
used. The characteristic x-ray counts were measured from the tumour vessel when 
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the head phantom was either full of water or empty. We shall discuss first the 
results for the tumours when the head phantom was full of water. 
The effects of the Gd concentration on the lateral and vertex positions as 
shown in Figure ‎4.2 and Figure ‎4.22 were investigated and studied. 
Concentrations of Gd were assessed using to 30 minutes of detector live time to 
measure characteristic x-ray emissions from the tumour vessel which contained 
Gd. Depending on the tumour vessel volume and the detected count rate, the 
chosen Gd concentrations investigated were different. These concentrations were 
15.73, 31.45, 47.18, 62.90, and 78.63 mg/ml for the tumour with a diameter of 1.0 
cm, while for the tumour with a diameter of 2.0 cm the concentrations were 22.47, 
44.93, 67.4, and 78.63 mg/ml. The Gd concentrations for the tumour with a 
diameter of 3.0 cm were 5.62, 28.08, 50.55, 61.78, and 78.63 mg/ml. Finally, the 
concentrations of the Gd for the 2.0 x 4.0 cm tumour were 8.28, 24.83, 41.38, 
57.94, and 78.63 mg/ml. 
The minimum value of the Gd concentration for each of the above four 
tumours was limited by the minimum detectable concentration set by the detector. 
It should be mentioned that the detection of the characteristic x-ray, emitted for a 
concentration below the minimum value for each of the above tumours, was very 
difficult even if the detection time was doubled. The maximum Gd concentration 
was limited by its concentration in the Magnevist, where one millilitre of 
Magnevist solution contains 469 mg of gadopentetic acid, and dimeglumine salt 
which corresponds to 78.63 mg of Gd. 
The results in Figure ‎4.3 to Figure ‎4.6 and Figure ‎4.23 to Figure ‎4.26 show 
that the total counts increased as the concentration of the Gd in the tumour vessel 
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(or the total amounts of Gd) increased as expected. The relation between the 
counts and the concentration for each measurement, does not follow a straight line 
possibly due to self absorption of the x-ray emissions inside the tumour vessel. 
This means that attenuation of both incident radiation and characteristic x-ray 
radiation took place inside the tumour vessel containing Gd. As the Gd 
concentration (or total amount) increases, the emitted characteristic x-ray is 
partially absorbed within the tumour because of the effect of the large atomic 
number of the Gd, which is 64. 
The other factor impacting on the experimental outcome is the location of 
the tumour vessel inside the head phantom (i.e., the depth of the tumour as 
measured from the interior wall of the head phantom surface to the centre of the 
tumour vessel). Measurements showed that at a depth of 2.0 cm for the tumour 
vessel with a diameter of 1.0 cm and also, at a depth of 2.5 cm for tumours size of 
2.0 cm, 3.0 cm, and 2.0 x 4.0 cm with a minimum concentration of Gd, the total 
count was not detectable.  Furthermore, it was clear that the deeper the tumour 
was inside the head phantom, the lower the counts were, owing to the increased 
distance from the CdTe detector and from the Americium source and owing to the 
attenuated and absorption of incident as well as emitted characteristic x-ray in the 
water inside the tumour and in the head phantom. This attenuation showed clearly 
in the highest concentration of Gd that was obtained by a full tumour vessel with 
Gd (78.63 mg/ml) in the lateral position. 
The total count obtained from a 2.0 cm tumour vessel was reduced from 
2.58 x 10
5
 ±508, at a depth of 1.0 cm, to 9.30 x 10
4
 ±305 counts at a depth of 2.5 
cm which was the last depth that Gd concentration was detected. In the tumour 
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vessel of 3.0 cm diameter the counts were reduced from 5.83 x 10
5
 ± 763 at 1.5 
cm depth to 7.74 x 10
5
 ± 278 count at a depth of 4.5 cm. It also occurred in the 
oval tumour 2.0 x 4.0 cm. The total count was reduced from 4.81 x 10
5
 ± 693 at 
1.5 cm depth to 4.67 x 10
4 
± 216 obtained at depth 3.5 cm.  Although the tumour 
is not a point source and counts do not follow exactly the inverse square law, yet 
attenuation, due to increased distance, is more effective than absorption. As the 
concentration or total amount of Gd increases, it increases the portion of emitted 
characteristics x-ray that is absorbed within the tumour vessel. Counts versus 
tumour depth at different concentrations are shown in Figure ‎4.7 to Figure ‎4.10 
and from Figure ‎4.27 to Figure ‎4.30, clearly the deeper the tumour, the lower the 
counts. 
The effect of water absorption (water is equivalent to biological tissue, as 
effective atomic number of water and tissue are both 7.4) was found when the 
experiment was repeated without water inside the head phantom as shown in 
Figure ‎4.3 to Figure ‎4.6. In these figures, the counts are lower for the head 
phantom containing water, than those of the empty head phantom under the same 
conditions (i.e., tumour size, tumour depth, and Gd concentration). The results of 
the characteristic x-ray, between the head phantom with and without water, are 
shown in Figure ‎4.24 in the tumour vessel of 2.0 cm diameter at a depth of 2.0 cm 
and containing 78.63 mg/ml of Gd concentration at the vertex position. 
The total count from the head phantom containing water was 1.50 x 10
5
 ± 
387 compared with 2.18 x 10
5
 ± 467counts from the head phantom without water. 
The total count was reduced by factor 1.5. On the other hand, at a depth of 4.5 cm 
in the tumour vessel of 3.0 cm diameter, the total count, obtained from head 
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phantom containing water, was 6.38 x 10
4
 ± 253 compared with 2.71 x 10
5
 ± 520 
counts from the empty head phantom (see Figure ‎4.25). Figure ‎4.26 showed that 
counts were reduced by four times when an irregular tumour vessel of 2.0 x 4.0 
cm at a depth of 4.0 cm was used, where counts from head phantom containing 
water were 7.21 x 10
4
 ± 268 compared with 2.17 x 10
5
 ± 466 from head phantom 
without water. Generally, at the same conditions (i.e., tumour size, tumour depth, 
and Gd concentration) the total counts without water were higher. The only effect 
that is responsible for the difference in total counts, is the presence of water inside 
the head phantom. This water caused the absorption of the incident 59.5 keV and 
the x-ray emitted from the tumour vessel.  
The relationship between the measured attenuation and the calculated 
attenuation are shown in Figure ‎4.11 and Figure ‎4.31. These figures show clearly 
the reasonable of the measured attenuation with that calculated. 
It should be noted that for the tumour with a diameter of 1.0 cm, it was 
difficult to measure the characteristics x-rays that were emitted from the tumour 
vessel containing Gd in the head phantom filled with water because of the small 
size of the tumour vessel. Therefore, all of the experiments for the 1.0 cm 
diameter tumour vessel were conducted in the empty head phantom. Total counts 
can be measurable for the smallest tumour vessel (1.0 cm) inside the head 
phantom containing water by increasing the activity of the source. This also 
allows getting measurable total counts from the deepest site of the tumour vessel 
inside the head phantom containing water. 
Figure ‎4.3 to Figure ‎4.6 and Figure ‎4.23 to Figure ‎4.26 also showed that 
the gaps between each two lines of the dependence of the total counts on the 
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concentration for different depths were different but smaller when the head 
phantom was empty. This occurred because the absorption was greater when 
water was present inside the head phantom. The results show that it is possible to 
measure the low concentration of Gd in the deeper distances inside the head 
phantom, such as 5.5 cm, when the head phantom is empty. 
Total counts from the three types of the tumour size inside the head 
phantom, in the lateral and vertex positions, showed consistency and a tendency 
towards saturation at higher concentrations.  
In Figure ‎4.12 and Figure ‎4.32, the total count measurements were taken 
for the head phantom without water. The figures also show the results of the 1.0 
cm tumour as they were measurable for this case (unlike the case when the head 
phantom contained water). This confirms the conclusion that the differences in the 
counts are due to different tumour size and shape. Increasing the tumour vessel 
size, increases the total counts for the tumour vessel depths, shown in the figures. 
It can be observed that for the same total amount of Gd, different counts are 
obtained by using different shapes. The highest counts were obtained from 3.0 cm 
tumour. The 1.0 cm tumour gave the lowest counts because it contained the least 
amount of Gd. The same effect was observed for tumours at different depths. This 
is because a large portion of the tumour vessel was exposed to the gamma 
radiation emitted from the amercium-241 source. 
For example, for about 300 mg of Gd in the tumour vessel in the vertex 
position, the number of total counts is higher for the 2.0 x 4.0 cm tumour than that 
of the 2.0 cm. Using 750 mg of Gd, the 3.0 cm tumour gives higher counts than 
the 2.0 x 4.0 cm as shown in Figure ‎4.32. This is attributed to the geometrical 
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shape of the tumour vessel. Since the distance was taken from the centre of the 
tumour vessel, the different shapes can have Gd atoms that can be closer or farther 
away from the detector giving different total counts. 
It is clear from the measurements that curves are very consistent in their 
trend. For example increased concentration show that counts increase before a 
non-linear trend of the data toward a saturation region is attained. This can be 
seen in almost all the graphs. For similar trend is observed with an increasing 
amount of Gd. The counts with increased depth show a decrease that is also 
similar in all shapes and concentration. This again reveals the consistency of 
results. No curves show abnormal behaviour which confirms the accuracy of the 
measurements. Furthermore counts with and without water in the head phantom 
also show similar trends which physical explanation.  
The sizes and the shapes of the tumours in the brain were confirmed by 
radiographic film of the tumour vessels which contained different concentrations 
of Gd inside the head phantom filled with water as shown in Figure ‎4.13 to Figure 
‎4.20. The radiographic image was taken of a 3.0 cm diameter tumour vessel in the 
lateral position at 1.5 cm depth with different Gd concentrations such as 0.56, 
2.81, 5.62, 16.85, 28.08, 39.32, 50.55 and 78.63 mg/ml. As the Gd in the tumour 
vessel has a high atomic number and high density, the incident gamma radiation 
interaction would be increased, leading to increased photon absorption which in 
turn made the tumour vessel bright on the x-ray image (i.e., opaque to the x-rays). 
So, the greater the concentration of Gd, the clearer the tumour image appeared. 
The collection time used in this work was 30 minutes. This is too long a 
time for measuring instantaneous concentration but acceptable for measurements, 
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such as this where the skin entrance dose was limited to be less than 10 mGy [85]. 
On the other hand, the source activity used was 0.97 Ci (3.6x10
10
 Bq). In order to 
reduce counting time, source activity can be increased. A source activity of about 
100 Ci (3.7x10
12
 Bq) is practical and can reduce the collection time to about 0.3 
minutes (18 seconds). Even higher activity sources can be used. In industrial 
radiography, for example, 100 Ci of Iridium (
192
Ir) portable sources are used, even 
though 
192
Ir emits gamma rays of average energy of 400 keV, much higher than 
the 60 keV of 
241
Am. 
Reduction of time can also be achieved by using a higher efficiency 
detector. Our detector of CdTe has about 1 cm
2
 of cross sectional area while the 
cylindrical scintillation detector, 5.0 inch in diameter x 4.0 inch height, can have 
about 125 time higher counts. 
The‎300‎μg‎157Gd/g [58] is below the trend towards saturation region; the 
results fall in the linear region. Error possibility would be small. We had to 
increase the concentration in order to find where the saturation region would start. 
It may be possible in the future to develop a chemical pharmaceutical where a 
higher Gd concentration is possible. By increasing the source activity two orders 
of magnitude or increasing the detection efficiency or both, counts and the overall 
efficiency can increase 10
2 
times. In this case, the detection limit can be much less 
than Gd concentration that brain can take. 
The energy of 59.5 keV is quite suitable for this application. It is slightly 
above the 42.98 keV of Gd characteristics x-rays which make the probability of 
interaction high. At energy less then 50 keV the interaction is not possible while 
at higher energy, the probability of interaction will decrease.     
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 One of the main advantages of 
241
Am, is its long half-life. In such a case 
the source can be used for a very long time without affecting the sensitivity of the 
system.  
X-rays from an x-ray machine can be used as a radiation source but the 
continuous spectrum of radiation will make analysis more difficult. For example, 
with a continuous incident x-ray spectrum, the scattered radiation peak coming 
from different components will be very wide. The Gd characteristic peak x-rays 
might be lost in this case. Moreover, the length of the exposure in most diagnostic 
x-ray generators is small; a fraction of a second. We attempted to use an industrial 
x-ray machine in which the exposure can last longer. The spectrum was very 
difficult to analyse. The CdTe detector is most suitable for such applications as it 
is designed to measure x-rays in the range of 0-100 keV. Detectors, such as NaI 
(Tl) scintillation detector, can also be used, but the Gd 42.98 keV will be close to 
its lower energy detection limit. A plastic organic scintillation detector of lower 
limit of about 1 keV will be more suitable. Although a Germanium detector can 
also be used it is very expensive and needs cooling by liquid nitrogen.   
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Possible source of errors: 
Possible errors can be from the following 
1. Statistical variation of counts rate. A standard deviation is N , where N 
is the total counts. The total counts from the 2 cm diameter tumour in the 
head phantom containing water at depth 1.5 cm was 941580 (188316 
counts from the signal and 753264 background).  Thus the signal is 
188316 ± 970, where 970 =

941580 . Accordingly the ratio of one 
standard deviation to be the total counts 

NTotal /NSignal will be small.  
2. Error from depth measurements. As an example at 2 cm size tumour inside 
head containing water, the distance error is within ± 0.5 mm this 
correspond to counts variation of 2-5%.  
3. Error from concentration measurements. Depending  on how accurately 
we observe the volume of liquid added to the Magnevist. We expect this 
error not to exceed about 2–3%. 
4. Error from background subtraction. This is given by the counting system 
and estimated to be 2% in general. 
5. There might be other errors that are associated with line voltage stability, 
amplifier stability and computer based multichannel analyzer stability. 
These are not expected to be more than about 2%. 
6. Considering all possible errors we expect the total error should not exceed 
about 8%.          
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T 
0 
dx 
dV = A dx 
Io 
Counts due to interaction of radiation with tumour: 
A complete analytical solution of experimental data will be very difficult; 
but we may reduce the problem into a one dimensional.  The model below may 
present a reasonable explanation of the experimental measured data. It is not 
expected that this model will fits the experimental data perfectly, but provide a 
good explanation and a base for future improvement.  
For simplicity of the calculations we will assume that the tumour has the 
following shape shown in Figure  4.33. In this case the problem is reduced to one 
dimensional instead of three dimensional, which is very complicated to solve 
analytically. 
  
 
 
 
 
 
Figure  4.33: Tumour shape. 
 
 
 
 
 
 
 Detector 
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Reaction Rate (RR) with a strip of thickness dx within tumour is given by: 
 
R‎R‎(within‎atoms‎in‎strip‎dx)‎=‎I‎σ‎dN       
 
I = Incident Radiation intensity (59.5keV), 
dN = Number of atoms in a volume dV. 
σ‎=‎Cross‎section‎of‎reaction‎in‎a‎volume‎dV. 
dV= A dx 
 
The radiation undergoes attenuation given by: 
 
I = Io e 
– μx
             (7) 
 
μ‎=‎Linear‎attenuation‎coefficient‎of‎incident‎radiation‎within‎the‎tumour‎with‎ 
      Gd. 
 
Io = Intensity at the surface of the tumour. 
 
dN‎=‎(ρ‎A‎dx‎/‎M).‎NA      
 
ρ‎=‎Density‎of‎tumour‎with‎Gd. 
A = Cross sectional area of tumour. 
M = Molecular weight of the tumour. 
NA = Avogadro number.  
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Therefore: 
 
RR = Io e 
- μx
 σ‎(ρ‎A‎dx‎/‎M).‎NA         (8) 
 
After interaction, x-rays are emitted and detected by the detector. The 
emitted radiation of 42.98 keV will undergo attenuation on its way back to the 
detector of:   
 
e 
– μ`x
           (9) 
 
μ`‎is‎the‎linear‎attenuation‎coefficient‎of‎emitted‎x-rays. 
If K is the detection efficiency, including the geometry factor, the count rate at the 
detector (dc) due to interaction with the strip is given by: 
dc =  Io e 
- μx
 σ‎(ρ‎A‎dx‎/‎M).‎NA . e 
– μ`x
 . K     
Where Io,‎σ,‎A,‎NA,‎K‎and‎ρ‎are‎constants. 
The total counts rate (C) will be a result of the interaction of all strips. 
That is: 
   C =  (NA Io σ‎A‎ρ‎K‎/‎M)‎ 
T
0
e 
–(‎μ‎+‎μ`)x
  dx    
For simplicity we assumed K is also a constant  
 
C = (NA Io σ‎A‎ρ‎K‎/‎(‎μ‎+‎μ`)‎M)‎.‎[‎1‎– exp { - (‎μ‎+‎μ`)‎T}]‎‎(10) 
 
Since‎μ‎=‎μm ρ,‎μm and‎μm` are the mass attenuation coefficients.  
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C = (NA Io σ‎A‎ρ‎K‎/‎(μm ρ‎+‎μm`‎ρ)‎M)‎.‎[1– exp{-(μm +‎μm`)‎ρ.‎T}]‎‎(11) 
or 
C = (NA Io σ‎A‎K‎/‎(μm +‎μm`) M) . [1 – exp{-(μm +‎μm`)‎ρ.T}]‎‎(12) 
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Effect of increased concentration:  
The behaviour of the count rate can be explained with reference to 
equation number 12. Although this system does not exactly represent the real 
geometry; the derivations can reasonably describe the effect of changing the 
concentration‎(ρ)‎or‎the‎volume‎of‎the‎tumour‎(T.‎A). 
In equation (12), the factor (NA Io σ‎ A‎ K‎ /‎ (μm +‎ μm`) M) is a constant, the 
variation in count rate can be explained in terms of the factor 
 
1 – exp{-(μm +‎μm`)‎ρ.‎T} 
 
Since the concentration of Magnevist is directly proportional to the density 
(ρ)‎the‎effect‎of‎changing‎concentration‎can‎be‎explained‎in‎terms‎of‎ρ.‎The‎count‎
rate (C) for constant thickness, will increase gradually and exponentially, reaching 
a saturation count of  
 
NA Io A‎K‎/‎μm +‎μm` M 
 
This exponential increase in counts was observed in our experiments as 
can be seen in the lateral position from Figure ‎4.3 to Figure ‎4.6. It can also be 
seen in the vertex position from Figure ‎4.23 to Figure 3.26. The above equation 
provides reasonable explanation for self absorption. 
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Effect of self absorption with increased concentration on count rate for 
constant volume: 
 
The effect of self absorption is clear from equation (7) and (9). Incident as 
well as emitted radiation undergoes attenuation in different layers of the tumour. 
Accordingly, the count rate will not increase linearly with concentration reaching 
the upper value limit.   
 
 
Effect of increased volume at constant concentration: 
The effect of changing volume can be explained with reference to equation 
(10). If‎ the‎concentration‎ is‎ constant,‎μ‎ and‎μ`‎are‎constant.‎ In‎ the‎above‎model‎
only T will change. Clearly, the count rate will increase in similar fashion as the 
change in concentration. If T increases, the count rate increases, reaching an upper 
value limit. As the volume increases, the fraction of radiation that reaches the 
deeper layers will be small, according to equation (8). Similarly, the emitted 
radiation from the deeper layers undergoes attenuation on its way to the detector. 
An insignificant amount of radiation, emitted from deeper layers of the tumour, 
will reach the detector if the volume is large. 
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Figure  4.34: Schematic of radiation interaction inside head phantom. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.35: Schematic of affect of scattered radiation inside head phantom. 
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Effect of tumour position inside head phantom on count rate: 
Referring to Figure ‎4.34 above, the factors that affect the count rate are: 
 
1. Attenuation of incident radiation: 
The incident radiation of 59.5 keV from the source, will undergo 
attenuation in water before reaching the tumour. The attenuation is given by e 
– μ‎r
 
where‎μ‎is‎the‎linear‎attenuation‎coefficient‎in‎water‎of‎59.5‎keV‎gamma‎rays. 
 
2. Scattered radiation within water:  
Referring to Figure ‎4.35 part of the scattered radiation within the water, 
whose energy was greater than 42.98 keV reaches the tumour thereby increasing 
the reaction rate. This is not a significant interaction because the fraction of 
scattered radiation, whose energy is greater than 42.98 keV, is very small. 
 
3. Attenuation of emitted radiation: 
Referring to Figure ‎4.34, the emitted radiation will undergo attenuation 
given by e 
– μ`‎r
 where‎μ`‎is‎the‎linear‎attenuation‎coefficient‎in‎water‎of‎42.98‎keV‎
x-rays. 
 
4. Distance between source and tumour: 
The distance (r) between the source and the tumour, is approximately the 
same between the tumour and the detector. The larger the distance the more the 
divergence will be of incident and emitted radiation and the less will be the count 
rate and vice versa. Because the source and the tumour dimensions are not very 
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small compared to the distance (r), the inverse square relation will not apply 
perfectly here. 
The effect of distance (r) only alone can be seen with references to Figure 
‎4.7, Figure ‎4.8, Figure ‎4.9 and Figure ‎4.10 in the lateral position, and Figure ‎4.27, 
Figure ‎4.28, Figure 3.29 and Figure ‎4.30 in the vertex position. In which there is 
not water in the phantom and according no attenuation of the incident or emitted 
x-rays.  
 
In order to correlate the derived equation of the modelling with the 
empirical equation we use expansion series, as follows 
)()1(
3
1
)1(
2
1
)1(]ln[
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32
32
Bxxxx
and
Axxxx




 
x near 1.0, of an equation (B)  
Neglecting the constants, the similarity between equation (A) and (B) is 
clear, especially at low concentrations. As the concentration increases the 
deviation between the two equations increases in the derived model neither the 
distance between the tumour and detector in the equation nor the absorption in 
water of incident and emitted rays were not taken as a parameter. Accordingly we 
do not expect the derived model can explain the experimental all data. 
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Empirical fitting data equation: 
In order to develop empirical equations from the experimental 
measurements to determine the concentration when the counts; the size of the 
tumour and the depth are given. 
The equation is in the form of  
 
Y = A Ln (x) + B                                      (13) 
was utilised  
where Y = Counts measured from the experiment 
 X = Concentration of the Gd in a brain tumour vessel 
 A and B Are‎ the‎ equation’s‎ parameters‎ given‎ by‎ the‎ curve‎ fitting‎
tools for each depth (ranges from 0.5 cm to 4.5 cm), tumour 
size, and shape 
 
Table 4.1 shows the experiment results for a 1 cm
3
 brain tumour at several 
depths. Also, Figure ‎4.3 shows the counts for a fixed tumour volume. 
The Gd concentration varies with depth. From this a relationship between 
the depth the concentration can be deduced as discussed below. 
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Table  4.1: Counts for 30 min of Gd characteristic x-rays at different 
concentrations of Gd and different depths inside the head phantom of a 1.0 cm 
diameter tumour in the lateral position. 
 
 
 
 
 
 
 
 
 
 
Distance from 
Skull surface to 
Tumour centre  
(cm) 
 
Concentration of Gd(mg/ml) 
 
15.73 
 
31.45 
 
47.18 
 
62.9 
 
78.63 
 
0 .5  
2.89 x10
4 
± 170
 5.72 x10
4
 
± 239 
7.09 x10
4
 
± 266 
7.89 x10
4
 
± 281 
8.17 x10
4
 
± 286 
1 
1.98 x10
4
 
± 141 
3.80 x10
4
 
± 195 
4.98 x10
4
 
 ± 223 
6.50 x10
4
 
± 255 
7.42 x10
4
 
± 272 
1.5 
6.36 x10
3
 
± 80 
3.03 x10
4
 
± 174 
3.85 x10
4
  
± 196 
4.86 x10
4
 
± 220 
5.82 x10
4
 
± 241 
2 
- 
2.08 x10
4
 
±144 
3.13 x10
4
  
± 177 
3.79 x10
4
 
± 195 
4.77 x10
4
 
± 218 
2.5 - 
1.81 x10
4
 
± 135 
2.78 x10
4
  
± 167 
3.15 x10
4
 
± 177 
3.77 x10
4
 
± 194 
3 - 
1.56 x10
4
 
± 125 
2.20 x10
4
  
± 148 
2.80 x10
4
 
± 167 
3.11 x10
4
 
± 176 
3.5 - 
1.10 x10
4
 
± 105 
1.78 x10
4
  
± 134 
2.21 x10
4
 
± 149 
2.44 x10
4
 
± 156 
4 - 
8.75 x10
3
 
±94 
1.28 x10
4
  
± 113 
1.76 x10
4
 
± 133 
1.92 x10
4
 
±139 
4.5 - 
7.67 x10
3
 
± 88 
1.08 x10
4
  
± 104 
1.44 x10
4
 
± 120 
1.59 x10
4
 
± 126 
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Step one: 
Using the Excel curve fitting tools a general equation can be developed as 
follows. 
 
Using the counts versus concentrations for a 1.0 cm diameter tumour at 
different depths, curves of the fitting equations, as shown in Figure ‎4.3 are given 
by:  
 
Y0.5 = 33623 Ln(x) – 61329           R
2
 = 0.9811 
Y1.0 = 33595 Ln(x) – 75385           R
2
 = 0.9778 
Y1.5 = 31025 Ln(x) – 78816           R
2
 = 0.9914 
Y2.0 = 28389 Ln(x) – 77779           R
2
 = 0.9832                                  (14) 
Y2.5 = 20540 Ln(x) – 52404           R
2
 = 0.9858 
Y3.0 = 17295 Ln(x) – 44155           R
2
 = 0.9957 
Y3.5 = 14855 Ln(x) – 39890           R
2
 = 0.9917 
Y4.0 = 11922 Ln(x) – 32512           R
2
 = 0.9838 
Y4.5 = 9301 Ln(x) – 24562             R
2
 = 0.9885 
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Step Two: 
Table ‎4.2 lists the constant value (A and B) obtained from the curve fitting for 
each depth obtained from Figure ‎4.3.  
 
                Table  4.2: List of A & B constant values. 
Depth (cm) A B 
0.5 33623 61329 
1.0 33595 75385 
1.5 31025 78816 
2.0 28389 77779 
2.5 20540 52404 
3.0 17295 44155 
3.5 14855 39890 
4.0 11922 32512 
4.5 9301 24562 
 
Equations of A and B constant are obtained by drawing the constant, versus depth, 
as is clear in Figure ‎4.36 and Figure ‎4.37.  
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A = -147.09x2 - 6122.6x + 38754
R
2
 = 0.968
0
5000
10000
15000
20000
25000
30000
35000
40000
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Depths (cm)
 
Figure  4.36: Value of A parameter versus depth.  
 
 
 
 
 
 
B = -3941x2 + 6799.7x + 68293
R
2
 = 0.8428
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Figure  4.37: Value of B parameter versus depth. 
 
 
 
 110 
The above equation (13) was developed for a 1.0 cm
3
 tumour. 
In order to generalise these equations with other tumours, of different 
volumes and shapes, we allowed the parameters A and B to be a function of 
depth. A power series fitting equation was utilised. If depth is the fitting equation 
for A and B: 
 
A = -147.09 x Depth
^2
 -6122 x Depth + 38754                    (15) 
 
B = -3941 x Depth
^2
 + 6799.7 x Depth + 68293                  (16) 
 
The reason for equations 15 & 16 being of a second degree order, is 
mainly decided by the curve fitting tool function. Different fitting techniques, 
such as linear or exponential fitting, do not provide a good match for the original 
curve. The R- squared as shown in Figure ‎4.36 and Figure ‎4.37 for A and B 
constants are 0.968 and 0.8428, respectively. R-squared is defined as a number 
from 0 to 1 which shows how closely the estimated value for the trendline 
corresponds with the actual data. A fitting is most accurate when its R-squared 
value is near to 1. 
Putting equations (15) and (16) in equation (10), we have:  
 
Y = (-147.09 x Depth
^2
 -6122 x Depth + 38754) Ln(X) + (-3941 x Depth
^2
 
                +6799.7 x Depth + 68293)                        (17) 
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We find the solution for X: 
Y = A Ln(X) + B 
Ln (X) = 
A
BY 
 
X = e 
(Y- B)/A
 
Substituting the values of A and B in from the fitting equations yields the 
equations listed in Table ‎4.3, for different sizes with and without water in the head 
phantom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
Table  4.3: List of general equations for each tumour case. 
 
 
Tumours 
 
Equation for  calculating the Gd Concentration 
 
 
1 cm  
Lateral Empty 
 
e
[(Y+(-3941xDepth^2+6799.7xDepth+68293))/(-147.09xDepth^2-6122.6xDepth+38754)]
 
R
2
(R-sq) of A =  0.968                        R
2
(R-sq) of B = 0.8428 
 
 
1 cm  
Vertex Empty 
 
e
[(Y+(-998.6 x Depth^2 - 280.08 x Depth + 43755)/(312.3 x Depth^2 – 5454.6 x Depth +27377)]
 
R
2
(R-sq) of A = 0.9174                      R
2
(R-sq) of B = 0.6662 
 
 
2 cm  
Lateral Water 
 
e
[(Y+(119392 x Depth^2 – 378534 x Depth + 438507))/(44941 x Depth^2 – 173359 x Depth + 228789)]
 
R
2
(R-sq) of A = 0.9994                     R
2
(R-sq) of B = 0.971 
 
 
2 cm  
Lateral Empty 
 
e
[(Y+(34323 x Depth^2 – 337050 x Depth + 937722))/(
 
11705 x Depth^2 – 118667 x Depth + 344224)]
 
R
2
(R-sq) of A = 0.9731                     R
2
(R-sq) of B = 0.9669 
 
 
2 cm  
Vertex Water 
 
e
[(Y+(37461 x Depth^2 – 244739 x Depth + 446238))/(
 
19938 x Depth^2 – 129110 x Depth + 234474)]
 
R
2
(R-sq) of A =  0.9833                     R
2
(R-sq) of B = 0.9528 
 
 
2 cm  
Vertex Empty 
 
e
[(Y+(-10282 x Depth^2 + 67823 x Depth + 108468))/(
 
-1353.5 x Depth^2 – 435.96 x Depth + 102643)]
 
R
2
(R-sq) of A =  0.8183                    R
2
(R-sq) of B = 0.3875 
 
 
3 cm  
Lateral Water 
 
e
[(Y+(-3415.5 x Depth^2 - 43878 x Depth + 305855))/(
 
12063 x Depth^2 – 124976 x Depth + 349816)]
 
R
2
(R-sq) of A = 0.9487                     R
2
(R-sq) of B = 0.6654 
 
 
3 cm  
Lateral Empty 
e
[(Y+(11225 x Depth^2 - 116921 x Depth + 428058))/(
 
7615.9 x Depth^2 – 91428 x Depth + 348489)]
 
R
2
(R-sq) of A =  0.9863                   R
2
(R-sq) of B = 0.948 
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3 cm  
Vertex Water 
e
[(Y+(-22709 x Depth^2 + 45210 x Depth + 292154))/(
 
10022 x Depth^2 – 129398 x Depth + 406331)]
 
R
2
(R-sq) of A = 0.9127                     R
2
(R-sq) of B =  0.5668 
 
 
3 cm  
Vertex Empty 
 
e
[(Y+(396.1 x Depth^2 - 41190 x Depth + 298212))/(
 
4685 x Depth^2 – 66208 x Depth + 290691)]
 
R
2
(R-sq) of A = 0.987                       R
2
(R-sq) of B =  0.9626 
 
 
2x4 cm  
Lateral Water 
 
e
[(Y+(81895 x Depth^2 - 477240 x Depth + 706859))/(
 
36012 x Depth^2 – 220451 x Depth + 354437)]
 
R
2
(R-sq) of A =  0.9587                   R
2
(R-sq) of B =  0.9511 
 
 
2x4 cm  
Lateral Empty 
 
e
[(Y+(17127 x Depth^2 - 153841 x Depth + 410260))/(
 
8402.6 x Depth^2 – 81492 x Depth + 237969)]
 
R
2
(R-sq) of A = 0.9021                    R
2
(R-sq) of B = 0.8686 
 
 
2x4 cm  
Vertex Water 
 
e
[(Y+(77621 x Depth^2 -535582 x Depth + 983429))/(
 
36843 x Depth^2 – 272599 x Depth + 533931)]
 
R
2
(R-sq) of A = 0.9712                    R
2
(R-sq) of B = 0.9562 
 
 
2x4 cm  
Vertex Empty 
 
e
[(Y+(- 10167 x Depth^2 + 47188 x Depth + 77641))/(
 
-941.14 x Depth^2 – 16795 x Depth + 152994)]
 
R
2
(R-sq) of A = 0.9572                    R
2
(R-sq) of B = 0.8335 
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Minitab Regression Equation  
Another method was used to calculate the Gd concentration in the tumour 
vessel inside a head phantom, with and without water. This method was 
regression equation determined by using the Minitab programme.   
Minitab is a statistical software programme used for data analysis 
capabilities.   
The regression equation is 
 
Y‎=‎β1‎+‎β2‎*‎LogG‎+‎β3‎*‎Depth‎‎‎‎‎‎‎‎‎‎‎(18) 
 
Where Y = Counts measured from the experiment 
 G = Gadolinium concentration /(mg/ml)  
 Β1,2,3  Parameters given by regression tools 
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Table  4.4: Log G and counts measurement at different concentrations and depths 
                     inside a head phantom of 1 cm
3
, in the lateral position.  
 
Tumour depth 
(cm) 
 
Gadolinium concentration 
(mg/ml) 
 
Counts 
 
 
LogG 
 
 
0.50 15.70 28852.00 2.75 
1.00 15.70 19775.00 2.75 
1.50 15.70 6361.00 2.75 
0.50 31.50 57233.00 3.45 
1.00 31.50 38027.00 3.45 
1.50 31.50 30260.00 3.45 
2.00 31.50 20776.00 3.45 
2.50 31.50 18126.00 3.45 
3.00 31.50 15635.00 3.45 
3.50 31.50 10958.00 3.45 
4.00 31.50 8750.00 3.45 
4.50 31.50 7670.00 3.45 
0.50 47.20 70920.00 3.85 
1.00 47.20 49774.00 3.85 
1.50 47.20 38477.00 3.85 
2.00 47.20 31259.00 3.85 
2.50 47.20 27817.00 3.85 
3.00 47.20 21992.00 3.85 
3.50 47.20 17847.00 3.85 
4.00 47.20 12829.00 3.85 
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4.50 47.20 10804.00 3.85 
0.50 62.90 78862.00 4.14 
1.00 62.90 64980.00 4.14 
1.50 62.90 48550.00 4.14 
2.00 62.90 37937.00 4.14 
2.50 62.90 31460.00 4.14 
3.00 62.90 28012.00 4.14 
3.50 62.90 22072.00 4.14 
4.00 62.90 17644.00 4.14 
4.50 62.90 14407.00 4.14 
0.50 78.60 81666.00 4.36 
1.00 78.60 74184.00 4.36 
1.50 78.60 58218.00 4.36 
2.00 78.60 47700.00 4.36 
2.50 78.60 37686.00 4.36 
3.00 78.60 31148.00 4.36 
3.50 78.60 24401.00 4.36 
4.00 78.60 19206.00 4.36 
4.50 78.60 15908.00 4.36 
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The data shown in Table ‎4.4 were used to obtain the regression equation which is:  
 
 
Counts = - 35396 + 26271 LogG - 13942 Depth                           (19) 
 
 
From the equation (15) the amount of concentration is solved for G: 
 
Y‎=‎β1‎+‎β2‎*‎LogG‎+‎β3‎*‎Depth 
LogG = 
2
3 1

 DepthY 
 
G = e 
(Y- β1+‎β3‎Depth)‎/‎β2 
 
By using Regression Analysis: Counts versus LogG, and Depth, different 
equations are obtained for different tumour vessel positioning, as shown in Table 
‎4.5.  
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Table  4.5: List of Gd concentration equations for each tumour case using Minitab 
software. 
 
Tumours case 
 
 
Equation for calculating the Gd concentration 
 
1 cm 
Lateral Empty 
 
e 
((Y + 35396 + 13942 Depth)/ 26271)
 
R
2
(R-sq) = 0.904 
1 cm  
Vertex Empty 
 
e 
((Y + 19074 + 9926 Depth)/ 18370)
 
R
2
(R-sq) = 0.917 
2 cm  
Lateral Water 
 
e 
((Y + 11672 + 104230 Depth)/ 80687)
 
R
2
(R-sq) = 0.931 
2 cm  
Lateral Empty 
 
e 
((Y + 109906 + 50993 Depth)/ 106328)
 
R
2
(R-sq) = 0.838 
2 cm  
Vertex Water 
 
e 
((Y - 23766 + 125175 Depth)/ 87997)
 
R
2
(R-sq) = 0.952 
2 cm  
Vertex Empty 
 
e 
((Y + 79639 + 36751 Depth)/ 84138)
 
R
2
(R-sq) = 0.958 
3 cm  
Lateral Water 
 
e 
((Y - 125209 + 139420 Depth)/ 133741)
 
R
2
(R-sq) = 0.876 
3 cm  
Lateral Empty 
 
e 
((Y - 198421 + 99569 Depth)/ 131741)
 
R
2
(R-sq) = 0.877 
3 cm  
Vertex Water 
 
e 
((Y - 144282 + 175695 Depth)/ 164329)
 
R
2
(R-sq) = 0.870 
3 cm  
Vertex Empty 
 
e 
((Y - 114655 + 78347 Depth)/ 124162)
 
R
2
(R-sq) = 0.883 
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2x4 cm  
Lateral Water 
 
e 
((Y - 28542 + 110047 Depth)/ 95300)
 
R
2
(R-sq) = 0.80 
2x4 cm  
Lateral Empty 
 
e 
((Y - 40555 + 51403 Depth)/ 79201) 
R
2
(R-sq) = 0.808 
2x4 cm  
Vertex Water 
 
e 
((Y - 169009 + 115071 Depth)/ 83709) 
R
2
(R-sq) = 0.892 
2x4 cm  
Vertex Empty 
 
e 
((Y - 105323 + 54294 Depth)/ 75542) 
R
2
(R-sq) = 0.921 
 
 
The above equations in Table ‎4.3 and Table ‎4.5 provide a good indication 
of the Gd concentration as obtained from the practical measurements with slight 
differences. This is contributed to the accuracy of the curve fitting method. 
The problem with the above approach is that the above equation is only 
valid for the specific case study (i.e. e. 1.0 cm
3
, lateral position of the head 
phantom empty) and cannot be implemented in other cases (e.g., 1.0 cm
3
 vertex 
position of the head phantom empty). Each case requires its own equation driven 
by the same steps as above. Refer to Table ‎4.3 and Table ‎4.5 for a list of the 
equations for different sized tumours with and without water, inside the head 
phantom. 
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Application of this work in treatment: 
1. Neutron capture therapy with maximum Gd concentration: 
This work has an immediate application in the real treatment of NCT. 
Using a geometry similar to the one used here, measurements (count rate) can be 
taken at several times during exposure to incident gamma radiation, for the 
purpose of finding the time of maximum Gd concentration. At maximum Gd 
concentration, neutron treatment can start and maximum dose will be delivered to 
the tumour. The concentration or the total amount of Gd in the tumour will 
determine the dose delivered. This is significant for any radiation therapy 
treatment. 
2. Diagnostic Imaging: 
This method can be used for tumour imaging purposes. Again, the count 
rate can be measured continuously, until the maximum value is reached. At this 
stage imaging by x-ray radiography, from different projects can take place. This 
accurately locates the tumour position. This can be easier than the MRI process 
which usually takes much longer time (  20 – 60 min). The patient is expected to 
stay without any movement; a process that is of discomfort to patients. Moreover, 
Gd may start to be eliminated from the tumour, if the process is too long.  
 
 
 
 
 
 
 121 
CHAPTER 5 
 
CONCLUSIONS 
 
An analysis of Gd concentration in the brain tumour vessel by XRF 
provided very useful information. It suggested the effective dose delivery to the 
tumour and what preventive measures should be taken to reduce the dose to the 
healthy tissue. 
The dose delivered to the tumour is of prime interest to therapists. Because 
the Gd compounds gradually build up in the tumour, followed by elimination, it is 
important to know the time when the highest concentration is reached, in order to 
give the highest dose. 
Measuring the concentration of Gd leads to dose assessment as well as to 
the time it takes to reach the highest concentration at which treatment can start. It 
should be mentioned that the time needed for the concentration to reach a 
maximum value, depends on each individual human body and can differ from one 
patient to another. Individual measurement of Gd concentration is therefore vital. 
Other techniques, such as MRI, are qualitative and do not provide 
concentration values. Moreover, it is time consuming and impractical for 
detecting when the highest concentration is reached. The best time to use this 
technique is immediately prior to the treatment procedure. It is also useful to 
measure the concentration immediately after treatment, in order to know how 
much Gd has been eliminated. Measurement during treatment is also possible. 
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The purpose of this research was to provide a method for analysis of the 
amount of Gd that was in the brain tumour vessel, where the Gd atoms, in the 
tumour vessel, were excited by a 36 GBq (0.97 Ci) 
241
Am source that emits 
gamma rays of 59.54 keV, in 35.7 % of it’s decays causing the Gd atoms, to emit 
a characteristic fluorescence at 42.98 keV in the resulting X-ray fluorescence 
spectrum. The intensity of the XRF radiation was proportional to the amount of 
Gd present in the brain tumour vessel. A Cadmium Telluride (CdTe) detector was 
used to evaluate and make an analysis of the Gd concentration. Determinations of 
the Gd content were obtained directly from the detector measurements of XRF 
from the exposed tumour vessel. Depending on the size of the tumour vessel, a 
depth was chosen from the skull surface to the centre of the tumour vessel. The 
positioning of the head phantom was selected to be either in the lateral and vertex 
positions.  Different sizes of tumour vessels, such as spherical tumour vessels of 
1.0, 2.0, 3.0 cm and an oval tumour vessel of 2.0 cm diameter and 4.0 cm length, 
containing the Gd agent were used. They were placed at different depths inside a 
head phantom at different positions in front of the detector and the source for the 
measurements. Different concentrations of Gd were subjected to 30 minutes of 
detector live time, and the characteristic x-ray emission was measured. The Gd 
concentrations which were investigated started from 5.62 and ranged up to 78.63 
mg/ml.  
These levels were selected because the lowest concentration used, detected 
by the detector, corresponded to 5.62 mg of Gd per millilitre of the brain tumour 
volume. The highest concentration used was 78.63 mg/ml. Different parameters 
impact on the experiment outcome, in terms of the total counts. The first 
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parameter was the amount of the Gd in the tumour vessel. Increasing the amount 
of Gd in the tumour vessel leads to increases in the total counts detectable. Total 
counts proportionally increased as the concentration and total amounts of Gd 
increased which as one would expect. The relation is not a straight line, possibly 
due to self absorption of the characteristics x-rays inside the tumour. As the 
concentration or the total amount of Gd increased, a portion of emitted 
characteristics x-rays were absorbed within the tumour containing Gd which has a 
much higher attenuation compared to that containing water and that because Gd is 
a chemical element in the periodic table that has atomic number 64 which 
therefore would increase photon absorption leading to a reduction in the detected 
total counts. 
The second effect, which impacted on the experimental outcome, was the 
location of the tumour inside the head phantom. This effect was studied at 
different distances from the surface of the head phantom to the centre of the 
tumour vessel. These depths, ranged from 0.5 cm to 5.5 cm between the centre of 
the tumour and interior wall of the head phantom surface. The results showed it 
was possible to measure the lower concentration of the Gd, for deeper distances 
inside the head phantom, such as the case of a depth of 5.5 cm. Furthermore, it 
was clear, that the deeper the tumour inside the head phantom, the lower the 
counts, due to the increased distance from the detector. Because of the size of the 
tumour vessel of 1.0 cm diameter, it was difficult to measure the characteristic x-
rays that were emitted from the tumour, containing Gd in the head phantom which 
was filled with water to equivalent biological tissue. Consequently, all the 
experiments were conducted in empty head phantoms.  
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 The study showed that it is possible to measure Gd in the brain tumour 
vessel by using XRF. It also provided information concerning those aspects of 
radiotherapy planning that need the most attention to optimise the dose treatment 
in radiotherapy. One more advantage of this method can be understanding the 
tumour Gd uptake, where the blood supply in the vessels of the cancer tumour is 
very limited. A benign tumour has more blood supply. Therefore, this study may 
give some information about the pathology of the tumour. 
The activity of the source directly affects the count rate. In this work 30 
minutes counting time was required. In order to reduce the count rates the source 
activity needs to be increased. At 100 Ci source the same counts can be obtained 
in 0.3 minutes (18 seconds). This is a very practical and fast measurement and can 
provide instantaneous concentration values of Gd during the build-up in the 
tumour or the elimination from it. 
Our work suggests that a total collected count depends not only on the 
total amount of Gd present, but also on the shape, size and depth of the tumour. 
Fortunately these parameters can be found by using ordinary and rapid 
radiography which gives instantaneous data, as shown in this work. It should be 
mentioned a radiographic film was used in this work. If digital radiography (DR) 
or computerised radiography had been used, a better image could have been 
obtained.  
The gamma rays emitted from the source are of energy 59.5 keV. This is 
adequate energy for such an application. The absorption by the Gd atom for a 
lower energy close to that of the binding energy of Gd (50.23 keV) can be higher. 
But by using lower energy the attenuation in the head phantom contain water will 
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be higher as well. For a higher energy source the attenuation in water is lower but 
the absorption cross section by Gd will be lower as well. We recommend that the 
lower energy require should be investigated. Unfortunately, there are not many 
sources of lower energy with a long enough half life to make them practical for 
such applications. Most available sources that emit 40 – 60 keV have a short half 
life.   
Total numbers of examinations were 478; at the vertex position were 232 
comparing the following cases: 39 were for the 1.0 cm spherical tumour, 55 were 
for the 2.0 cm spherical tumour, 75 were for the 3.0 cm spherical tumour and 63 
were for the 2.0 x 4.0 cm ellipsoid tumour. While the total numbers of 
examinations in the lateral position were 246 comparing the following cases:  39 
were for the 1.0 cm spherical tumour, 55 were for the 2.0 cm spherical tumour, 75 
were for the 3.0 cm spherical tumour and 77 were for the 2.0 x 4.0 cm ellipsoid 
tumour. 
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